

TREVENA INC  
Form DEF 14A  
April 02, 2019  
Table of Contents

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**SCHEDULE 14A**

**Proxy Statement Pursuant to Section 14(a) of  
the Securities Exchange Act of 1934 (Amendment No. )**

Filed by the Registrant  X

Filed by a Party other than the Registrant  O

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material under §240.14a-12

**Trevena, Inc.**

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.
- Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
  - (1) Title of each class of securities to which transaction applies:
  - (2) Aggregate number of securities to which transaction applies:
  - (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
  - (4) Proposed maximum aggregate value of transaction:
  - (5) Total fee paid:
- Fee paid previously with preliminary materials.
-

## Edgar Filing: TREVENA INC - Form DEF 14A

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

- (1) Amount Previously Paid:
  - (2) Form, Schedule or Registration Statement No.:
  - (3) Filing Party:
  - (4) Date Filed:
-

Table of Contents

April 2, 2019

955 Chesterbrook Boulevard, Suite 110

Chesterbrook, PA 19087

Dear Trevena Stockholder:

On behalf of the Trevena, Inc. Board of Directors and our senior management team, we are pleased to invite you to our 2019 Annual Meeting of Stockholders on May 16, 2019. The attached Notice of 2019 Annual Meeting of Stockholders and proxy statement contain important information about the business to be conducted at the Annual Meeting.

Your vote is very important. Whether or not you plan to attend the Annual Meeting, we hope that you will vote as soon as possible. Please review the instructions on each of your voting options described in the Important Notice Regarding the Availability of Proxy Materials. Additional instructions on how to vote can be found on pages 2 through 4 of the proxy statement.

We look forward to seeing you at the Annual Meeting. As always, thank you for your continued support of Trevena.

Sincerely,

**Carrie L. Bourdow**  
*President and Chief Executive Officer*

Table of Contents

NOTICE OF 2019 ANNUAL MEETING OF STOCKHOLDERS

**Date and Time:** Thursday, **May 16, 2019** at 8:30 a.m.

**Place:** 955 Chesterbrook Boulevard, Suite 112  
Chesterbrook, PA 19087

**Items of Business:** **Proposal 1:** Election of the three director nominees named in the proxy statement for terms expiring at the 2022 Annual Meeting of Stockholders.

**Proposal 2:** Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2019.

Consideration of any other business properly brought before the Annual Meeting.

**Record Date:** Tuesday, March 19, 2019. Only Trevena stockholders of record at the close of business on the record date are entitled to receive this notice and vote at the Annual Meeting and any adjournment or postponement of the Annual Meeting.

A list of stockholders of the Company entitled to vote at the Annual Meeting will be available for inspection by any stockholder at the Annual Meeting and during normal business hours at the Company's corporate offices during the 10-day period immediately prior to the date of the Annual Meeting.

**Proxy Voting:** Your vote is very important, regardless of the number of shares you own. We urge you to promptly vote by telephone, by using the Internet, or, if you received a proxy card or instruction form, by completing, dating, signing and returning it by mail. For instructions on voting, please see Questions and Answers about Voting beginning on page 2.

April 2, 2019

By order of the Board of Directors,

**Joel S. Solomon**  
*Corporate Secretary*

**EACH STOCKHOLDER IS URGED TO VOTE BY COMPLETING, SIGNING AND RETURNING THE PROXY CARD IN THE ENVELOPE PROVIDED OR BY VOTING VIA THE INTERNET OR BY TELEPHONE, IN EACH CASE IN THE MANNER DESCRIBED IN THE NOTICE REGARDING AVAILABILITY OF PROXY MATERIALS. IF A STOCKHOLDER DECIDES TO ATTEND THE ANNUAL MEETING, HE OR SHE MAY, IF SO DESIRED, REVOKE THE PROXY AND VOTE THE SHARES IN PERSON.**

Table of Contents

**IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS  
FOR THE ANNUAL STOCKHOLDER MEETING TO BE HELD ON MAY 16, 2019**

**Our 2019 Notice of Annual Meeting and Proxy Statement and 2018 Annual Report to Stockholders are available at [www.proxyvote.com](http://www.proxyvote.com).**

Please see Information About the 2019 Annual Meeting beginning on page 1 of this proxy statement for the following information:

- Date, time, and location of the 2019 Annual Meeting of Stockholders;
  - How to obtain directions to the Annual Meeting;
  - How to vote in person at the Annual Meeting;
  - An identification of each separate matter to be acted on at the Annual Meeting; and
  - The recommendations of our Board of Directors regarding those matters.
-

Table of Contents

TABLE OF CONTENTS

<b><u>INFORMATION ABOUT THE 2019 ANNUAL MEETING</u></b>	<b>1</b>
<u>Questions and Answers About the Proxy Materials</u>	1
<u>Questions and Answers About Voting</u>	2
<b><u>CORPORATE GOVERNANCE</u></b>	<b>5</b>
<u>Governance Policies and Practices</u>	5
<u>Role of the Board and Leadership Structure</u>	6
<u>Other Board Practices</u>	7
<u>Board Meetings and Committees</u>	8
<u>Director Independence</u>	10
<u>Code of Ethics</u>	10
<u>Certain Transactions</u>	10
<b><u>PROPOSAL 1. ELECTION OF DIRECTORS</u></b>	<b>12</b>
<u>Process for Selecting and Nominating Directors</u>	12
<u>Board of Directors - Nominees</u>	13
<b><u>NON-EMPLOYEE DIRECTOR COMPENSATION</u></b>	<b>18</b>
<u>Overview</u>	18
<u>Director Compensation Program</u>	18
<u>Director Compensation Table for 2018</u>	19
<b><u>PROPOSAL 2. RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS</u></b>	<b>20</b>
<b><u>REPORT OF THE AUDIT COMMITTEE</u></b>	<b>22</b>
<b><u>EXECUTIVE COMPENSATION</u></b>	<b>23</b>
<u>Overview</u>	23
<u>2018 Summary Compensation Table</u>	26
<u>Narrative to 2018 Summary Compensation Table</u>	27
<u>Outstanding Equity Awards at Year-End 2018</u>	32
<u>Executive Officer Agreements</u>	33
<b><u>OWNERSHIP OF TREVENA COMMON STOCK</u></b>	<b>36</b>
<u>Security Ownership of Certain Beneficial Owners, Directors and Executive Officers</u>	36
<u>Section 16(a) Beneficial Ownership Reporting Compliance</u>	37
<b><u>2020 ANNUAL MEETING AND RELATED MATTERS</u></b>	<b>38</b>

Notice of 2019 Annual Meeting of Stockholders and Proxy Statement

Table of Contents

INFORMATION ABOUT THE 2019 ANNUAL MEETING

**QUESTIONS AND ANSWERS ABOUT THE PROXY MATERIALS**

**Why did I receive proxy materials? What is included in the proxy materials?**

Our Board of Directors is soliciting your proxy to vote at the 2019 Annual Meeting of Stockholders. You received proxy materials because you owned shares of Trevena common stock at the close of business on March 19, 2019, the record date, and that entitles you to vote at the 2019 Annual Meeting of Stockholders.

Proxy materials include the notice of annual meeting of stockholders, the proxy statement and our annual report on Form 10-K for the year ended December 31, 2018 and, if you received paper copies, a proxy card or voting instruction form. The proxy statement describes the matters on which the Board of Directors would like you to vote, and provides information about Trevena that we must disclose under Securities and Exchange Commission (SEC) regulations when we solicit your proxy.

Your proxy will authorize specified persons, each of whom also is referred to as a proxy, to vote on your behalf at the Annual Meeting. By use of a proxy, you can vote whether or not you attend the Annual Meeting in person. The written document by which you authorize a proxy to vote on your behalf is referred to as a proxy card.

We intend to mail these proxy materials on or about April 2, 2019 to all stockholders of record entitled to vote at the Annual Meeting.

**How can I get electronic access to the proxy materials?**

The proxy materials are available for viewing at [www.proxyvote.com](http://www.proxyvote.com). On this website, you may:

- vote your shares after you have viewed the proxy materials; and
- select a future delivery preference of paper or electronic copies of the proxy materials.

## Edgar Filing: TREVENA INC - Form DEF 14A

You may choose to receive proxy materials electronically in the future. If you choose to do so, you will receive an email with instructions containing an electronic link to the proxy materials for next year's annual meeting. You also will receive an electronic link to the proxy voting site.

Rules adopted by the SEC allow companies to send stockholders a notice of Internet availability of proxy materials only, rather than mail them full sets of proxy materials. This year, we chose to mail full packages of proxy materials to stockholders. However, in the future we may take advantage of this alternative notice only distribution option. If in the future we choose to send only such notices, they would contain instructions on how stockholders can access our notice of annual meeting and proxy statement via the Internet. It also would contain instructions on how stockholders could request to receive their materials electronically or in printed form on a one-time or ongoing basis.

If you hold your shares through a bank, broker or other custodian, you also may have the opportunity to receive the proxy materials electronically. Please check the information contained in the documents provided to you by your bank, broker or other custodian.

*We encourage you to take advantage of the availability of the proxy materials electronically to help reduce the environmental impact of the Annual Meeting.*



Table of Contents**QUESTIONS AND ANSWERS ABOUT VOTING****What am I voting on at the Annual Meeting?**

<b>Proposal</b>	<b>Description</b>	<b>Board's Vote Recommendation</b>	<b>Page</b>
1	Election of the three director nominees named in this proxy statement for terms expiring at the 2022 Annual Meeting of Stockholders	Vote <b>FOR</b> each of the nominees	12
2	Ratification of appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018	Vote <b>FOR</b>	20

**Could other matters be decided at the Annual Meeting?**

We are not aware of any other matters that will be presented and voted upon at the Annual Meeting. Our 2018 proxy statement described the requirements under our governance documents for properly submitting proposals or nominations from the floor at this year's Annual Meeting. The proxies will have discretionary authority, to the extent permitted by law, on how to vote on other matters that may come before the Annual Meeting.

**How many votes can be cast by all stockholders?**

Each share of Trevena common stock is entitled to one vote on each of the three directors to be elected and one vote on each of the other matters properly presented at the Annual Meeting. We had 92,353,638 shares of common stock outstanding and entitled to vote on March 19, 2019.

**How many votes must be present to hold the Annual Meeting?**

A majority of the issued and outstanding shares entitled to vote, or 46,176,820 shares, present in person or by proxy, are needed for a quorum to hold the Annual Meeting. Abstentions and broker non-votes (discussed below) are included in determining whether a quorum is present. We urge you to vote by proxy even if you plan to attend the Annual Meeting. This will help us know that enough votes will be present to hold the Annual Meeting.

**How many votes are needed to approve each proposal? How do abstentions or broker non-votes affect the voting results?**

## Edgar Filing: TREVENA INC - Form DEF 14A

The following table summarizes the vote threshold required for approval of each proposal and the effect on the outcome of the vote of abstentions and uninstructed shares held by brokers (referred to as broker non-votes). When a beneficial owner does not provide voting instructions to the institution that holds the shares in street name, brokers may not vote those shares in matters deemed non-routine. Only Proposal 1 below is deemed to be a non-routine matter, and as a result, your broker or nominee may not vote your shares on Proposal 1 in the absence of your instruction. Proposal 2 is considered to be a routine matter, and as a result, your broker or nominee may vote your shares in its discretion either for or against Proposal 2 even in the absence of your instruction. If you are a beneficial owner and want to ensure that all of the shares you beneficially own are voted for or against Proposal 2, you must give your broker or nominee specific instructions to do so.

Proposal Number	Summary Description	Vote Required for Approval	Effect of Abstentions	Effect of Broker Non-Votes
1	Election of directors	Plurality of votes cast	No effect	Not voted/No effect
2	Ratification of the appointment of independent auditor	Majority of shares present and entitled to vote	Counted against	Shares may be voted by brokers in their discretion but any non-votes have no effect

Signed but unmarked proxy cards will be voted for each proposal.

Table of Contents

**How do I vote if I own shares as a record holder?**

If your name is registered on Trevena's stockholder records as the owner of shares, you are the record holder. If you hold shares as a record holder on the record date, there are four ways that you can vote your shares.

- **Over the Internet.** Vote at [www.proxyvote.com](http://www.proxyvote.com). The Internet voting system is available 24 hours a day until 11:59 p.m. Eastern Time on Wednesday, May 15, 2019. Once you enter the Internet voting system, you can record and confirm (or change) your voting instructions.
- **By telephone.** Use the telephone number shown on your proxy card. The telephone voting system is available 24 hours a day in the United States until 11:59 p.m. Eastern Time on Wednesday, May 15, 2019. Once you enter the telephone voting system, a series of prompts will tell you how to record and confirm (or change) your voting instructions.
- **By mail.** If you received a proxy card, mark your voting instructions on the card and sign, date and return it in the postage-paid envelope provided. If you received only a notice of Internet availability but want to vote by mail, the notice includes instructions on how to request a paper proxy card. For your mailed proxy card to be counted, we must receive it before 8:30 a.m. Eastern Time on Thursday, May 16, 2019.
- **In person.** Attend the Annual Meeting or send a personal representative with a valid legal proxy.

**How do I vote if my Trevena shares are held by a bank, broker or custodian?**

If your shares are held by a bank, broker or other custodian (commonly referred to as shares held in street name), the holder of your shares will provide you with a copy of this proxy statement, a voting instruction form and directions on how to provide voting instructions. These directions may allow you to vote over the Internet or by telephone.

Proposal 2 is deemed to be a routine matter. Therefore, if you are a beneficial owner of shares registered in the name of your broker or other nominee and you fail to provide instructions to your broker or nominee as to how to vote your shares on this proposal, your broker or nominee will have the discretion to vote your shares on such proposal. Accordingly, if you fail to provide voting instructions to your broker or nominee, your broker or nominee can vote your shares on the proposal in a manner that is contrary to what you intend. For example, if you are against the approval of Proposal 2 but you do not provide any voting instructions to your broker, your broker can nonetheless vote your shares. For Proposal 2. While we do not expect any broker non-votes on either proposal, if you do not provide voting instructions and your broker or nominee fails to vote your shares, this will have the same effect as an Against vote. **If you are a beneficial owner of shares registered in the name of your broker or other nominee, we strongly encourage you to provide voting instructions to the broker or nominee that holds your shares to**

**ensure that your shares are voted in the manner in which you want them to be voted.**

If you hold shares in street name and want to vote in person at the Annual Meeting, you will need to ask your bank, broker or custodian to provide you with a valid legal proxy. You will need to bring the proxy with you to the Annual Meeting in order to vote. Please note that if you request a legal proxy from your bank, broker or custodian, any previously executed proxy will be revoked and your vote will not be counted unless you vote in person at the Annual Meeting or appoint another valid legal proxy to vote on your behalf.

**Can I change my vote?**

Yes. If you are a record holder, you may:

- Enter new instructions by telephone or Internet voting before 11:59 p.m. Eastern Time on Wednesday, May 15, 2019;
- Send a new proxy card with a later date than the card submitted earlier. We must receive your new proxy card before 8:30 a.m. Eastern Time on Thursday, May 16, 2019;
- Write to the Corporate Secretary at the address listed on page 38. Your letter should contain the name in which your shares are registered, the date of the proxy you wish to revoke or change, your new voting

Table of Contents

instructions, if applicable, and your signature. Your letter must be received by the Corporate Secretary before 8:30 a.m. Eastern Time on Thursday, May 16, 2019; or

- Vote in person (or send a personal representative with a valid proxy) at the Annual Meeting. Note that simply attending the Annual Meeting without voting in person will not, by itself, revoke your proxy.

If you hold your shares in street name, you may:

- Submit new voting instructions in the manner provided by your bank, broker or other custodian; or
- Contact your bank, broker or other custodian to request a proxy to vote in person at the Annual Meeting.

**Who will count the votes? Is my vote confidential?**

Trevena's Vice President of Finance, John P. Hamill, has been appointed Inspector of Election for the Annual Meeting. The Inspector of Election will determine the number of shares outstanding, the shares represented at the Annual Meeting, the existence of a quorum, and the validity of proxies and ballots, and will count all votes and ballots.

All votes are confidential. Your voting records will not be disclosed to us, except as required by law, in contested Board elections or certain other limited circumstances.

**Who pays for the proxy solicitation and how will Trevena solicit votes?**

We pay the cost of preparing our proxy materials and soliciting your vote. Proxies may be solicited on our behalf by our directors, officers, employees and agents by telephone, electronic or facsimile transmission or in person. We may choose to enlist the help of banks and brokerage houses in soliciting proxies from their customers and, in all cases, will reimburse them for their related out-of-pocket expenses.

**Where can I find the voting results of the Annual Meeting?**

## Edgar Filing: TREVENA INC - Form DEF 14A

We will publish the voting results of the Annual Meeting on a Current Report on Form 8-K filed with the SEC. The Form 8-K will be available online at [www.sec.gov](http://www.sec.gov) within four business days following the end of our Annual Meeting. If final voting results are not available to us in time to file a Form 8-K within four business days after the Special Meeting, we intend to file a Form 8-K to publish preliminary results and, within four business days after the final results are known to us, file an additional Form 8-K to publish the final results.

### ***IMPORTANT INFORMATION IF YOU PLAN TO ATTEND THE ANNUAL MEETING IN PERSON***

*You must be able to show that you owned Trevena common stock on the record date, March 19, 2019, in order to gain admission to the Annual Meeting. Please bring to the Annual Meeting the notice of Internet availability of proxy materials, a printed proxy card, or a brokerage statement or letter from your broker verifying ownership of Trevena shares as of March 19, 2019. You also must bring a valid government-issued photo ID. Registration will begin at 8:00 a.m. **Please note that you are not permitted to bring any cameras, recording equipment, electronic devices, large bags, briefcases or packages into the Annual Meeting.***

Table of Contents

CORPORATE GOVERNANCE

**GOVERNANCE POLICIES AND PRACTICES**

Trevena is committed to ensuring strong corporate governance practices on behalf of our stockholders. Trevena's Corporate Governance Guidelines, together with the charters of the Audit, Compensation and Nominating and Corporate Governance Committees, establishes a framework of policies and practices for our effective governance. Our Corporate Governance Guidelines, which are available at [investors.trevena.com/corporate-governance](http://investors.trevena.com/corporate-governance), address Board composition, leadership, performance and compensation, director qualifications, director independence, committee structure and roles, and succession planning, among other things. The Board, the Nominating and Corporate Governance Committee and the other committees regularly review their governance policies and practices and developments in corporate governance and update these documents as they deem appropriate for Trevena.

The following describes some of our most significant governance practices by area.

**BOARD STRUCTURE AND PROCESS**

- 9 Directors on Board
- 7 Independent Directors (78%)
- Classified Board Divided into Three Classes
- Diverse Board as to Composition, Skills and Experience
- Independent Chairman of the Board
- Independent Audit, Compensation, and Nominating and Corporate Governance Committees
- Annual Self-Evaluations of the Board and its Committees

**OVERSIGHT OF EXECUTIVE COMPENSATION**

- Pay-for-Performance Executive Compensation Philosophy
- Independent Compensation Consultant to the Compensation Committee
- Double-trigger Vesting of Equity on Change of Control
- No Tax Gross-up on Change of Control

**ALIGNMENT WITH STOCKHOLDER INTERESTS**

- High Percentage of Variable ( at risk ) NEO Pay
- Significant Portion of Director Compensation Delivered in Trevena Common Stock
- Restrictions on Hedging of Trevena Common Stock

For more information about our executive compensation governance policies and practices, see Executive Compensation beginning on page 23.



Table of Contents

**ROLE OF THE BOARD AND LEADERSHIP STRUCTURE**

The Board's primary role is the oversight of the management of Trevena's business affairs and assets in accordance with the Board's fiduciary duties to stockholders under Delaware law. To fulfill its responsibilities to our stockholders, Trevena's Board, both directly and through its committees, regularly engages with management, promotes management accountability and reviews the most critical issues that face Trevena. Among other things, the Board reviews the Company's strategy and mission, its execution on financial and strategic plans, and succession planning. The Board also oversees risk management and determines the compensation of the Chief Executive Officer (CEO), in consultation with the Compensation Committee. All directors play an active role in overseeing the Company's business strategy at the Board and committee levels. The Board is committed to meeting the dynamic needs of the Company and focusing on the interests of its stockholders and, as a result, regularly evaluates and adapts its composition, role, and relationship with management.

**Independent Board Members**

Trevena believes in the importance of a board comprised largely of independent, non-employee directors. Currently, the Board has determined that all Trevena directors, other than the Company's CEO, Carrie L. Bourdow, and former CEO, Maxine Gowen, are independent under Nasdaq listing standards and SEC rules. Similarly, at the committee level, all committee members are independent.

**Independent Chairman of the Board**

We separate the roles of the Chairman of the Board and CEO, and have appointed Leon O. Moulder, Jr., to serve as our independent Chairman. We believe that having a Chairman separate from the CEO helps to ensure independent oversight of the Company and the management team and contributes to strong governance practices. The Board regularly assesses the appropriateness of this leadership structure and has concluded that this structure is appropriate for Trevena at this time. The full Board evaluates the Chairman's performance on an annual basis.

The following table describes the key responsibilities that the Board has delegated to the Chairman of the Board:

**CHAIRMAN RESPONSIBILITIES**

- |  |  |
|--|--|
| • Serves as principal representative of the Board  | • Advises the CEO on issues of concern for the Board |
| • Develops schedule and agenda of Board meetings, in consultation with the CEO and other directors | • Leads the Board in CEO succession planning         |
| • Presides over Board and stockholder meetings   | • Engages in the director recruitment process        |

- Facilitates discussion among independent directors on key issues
- Acts as a liaison between the Board and management
- Represents the Company in interactions with external stakeholders, at the request of the Board

#### **Risk Oversight**

One of the Board's key functions is informed oversight of our risk management process. The Board does not have a standing risk management committee, but rather administers this oversight function directly through the Board as a whole, as well as through various Board standing committees that address risks inherent in their respective areas of oversight. In particular, our Board is responsible for monitoring and assessing strategic risk exposure, including a determination of the nature and level of risk appropriate for the Company. Our Audit Committee has the responsibility to consider and discuss our major financial risk exposures and the steps our management has taken to monitor and control these exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. The Audit Committee also monitors compliance with legal and regulatory requirements, in addition to oversight of the performance of our internal audit function. Our Nominating and Corporate Governance Committee monitors the effectiveness of our corporate governance guidelines, including whether they are successful in preventing illegal or improper liability-creating conduct. Our

Table of Contents

Compensation Committee assesses and monitors whether any of our compensation policies and programs has the potential to encourage excessive risk-taking. It is the responsibility of the committee chairs to report findings regarding material risk exposures to the Board as quickly as possible.

**OTHER BOARD PRACTICES**

Trevena employs a number of other practices directed to ensure the highest level of corporate governance oversight on behalf of its stockholders. The following table describes some of these practices in more detail.

**PRACTICES DIRECTED TO INDIVIDUAL TREVENA DIRECTORS**

**Limits on Public Company Directorships**

The Board does not believe that its directors should be prohibited from serving on boards of other organizations. However, the Nominating and Corporate Governance Committee takes into account the nature of and time involved in a director's service on other boards in evaluating the suitability of individual directors and making its recommendations to the Board. The Company expects that each of its directors will be able to dedicate the time and resources sufficient to ensure the diligent performance of his or her duties on the Company's behalf, including attending board and applicable committee meetings.

**Change in Director's Principal Position**

If a director changes his or her principal employment position, that director is required to tender his or her resignation to the Nominating and Corporate Governance Committee. The Committee will then recommend to the Board whether to accept or decline the resignation.

**Continuing Education for Directors**

The Board is regularly updated on Trevena's businesses, strategies, operations and employee matters, as well as external trends and issues that affect the Company. The Nominating and Corporate Governance Committee oversees the continuing education process and it encourages directors to attend continuing education courses relevant to their service on Trevena's Board. Trevena reimburses directors for expenses they incur in connection with continuing education courses.

**Attendance at Annual Meeting of Stockholders**

The Board expects directors and nominees for director to attend the Annual Meeting. In 2018, all of the directors attended the annual meeting of stockholders. Trevena anticipates that all directors will attend the 2019 Annual Meeting.

Table of Contents

**PRACTICES DIRECTED TO TREVENA BOARD PROCESSES**

<b>Board Executive Sessions</b>	As part of all regularly scheduled Board meetings, the Chairman presides over all executive sessions of the Board, including those sessions held solely with independent directors. At each regularly scheduled meeting held in 2018, the independent members of the Board met in executive session. Each Board committee also met in executive session on a regular basis in connection with their respective meetings.
<b>Director Access to Management</b>	Independent directors have unfettered access to members of senior management and other key employees.
<b>Independent Advisors</b>	The Board and its committees are able to access and retain independent advisors as and to the extent they deem necessary or appropriate.
<b>Management Succession Planning</b>	At the direction of the Chairman, the Board oversees management succession planning. As appropriate, the Board will develop and approve succession plans for the Company's CEO and review and approve succession plans for the Company's senior management together with the input of the Nominating and Corporate Governance Committee and the CEO.
<b>Annual Board Evaluation</b>	Each year, the Nominating and Corporate Governance Committee oversees the self-evaluation of the Board and its committees. Each Board committee also is responsible for conducting a self-assessment to identify potential areas of improvement. On an ongoing basis, directors offer suggestions and recommendations intended to further improve Board performance.

**PRACTICES DIRECTED TO TREVENA STOCKHOLDERS**

<b>Alignment of Director Compensation</b>	Trevena delivers a significant portion of its non-employee director compensation in the form of options to purchase Trevena common stock. For more information on non-employee director compensation, see page 18.
<b>No Stockholder Rights Plan ( Poison Pill )</b>	Trevena does not have a stockholder rights plan.

**BOARD MEETINGS AND COMMITTEES**

In 2018, there were 12 meetings of the Board, 15 meetings of the Nominating and Corporate Governance, Compensation and Audit committees of the Board, and 1 meeting of a special purpose committee of the Board. Overall director attendance at Board and committee meetings in 2018 was approximately 99%. Each director attended 90% or more of the aggregate of all meetings of the Board and committees on which he or she served during 2018. In addition to formal Board meetings, the Board engages with management throughout the year on critical matters and topics.

The Board has the following three standing committees: Nominating and Corporate Governance, Compensation, and Audit. In its discretion and subject to Delaware law, the Board and each committee may delegate all or a portion of its authority to subcommittees of one or more of its members. Additional information can be found in the committee charters adopted by the Board and available on Trevena's website at [investors.trevena.com/corporate-governance](http://investors.trevena.com/corporate-governance). Each committee member meets the independence standards required for the committee on which

he or she serves.

Table of Contents

**NOMINATING AND CORPORATE  
GOVERNANCE COMMITTEE**

Chair: Julie H. McHugh

Other Committee Members: Jake R. Nunn, Anne M. Phillips, M.D.

Meetings Held in 2018: 5

Primary Responsibilities:

- Assisting the Board by identifying qualified candidates for director, assessing director independence and recommending to the Board the director nominees.
- Making recommendations to the Board regarding the composition, organization and governance of the Board, including recommendations regarding the membership and chairperson of each Board committee.
- Reviewing, advising and reporting to the Board on the Board's membership, structure, organization, governance practices and performance.
- Developing, recommending and maintaining a set of Corporate Governance Guidelines applicable to the Company.
- Overseeing, together with the Board Chairman, the review and evaluation of the Board and its committees.

**COMPENSATION COMMITTEE**

Chair: Barbara Yanni

Other Committee Members: Leon O. Moulder, Jr., Anne M. Phillips, M.D.

Meetings Held in 2018: 6

Primary Responsibilities:

- Approving the Company's long-term strategy of compensation for employees and directors.
- Reviewing the corporate goals and objectives applicable to the compensation of the CEO, evaluating the CEO's performance in light of these goals and objectives and, based on this review and evaluation, recommending the compensation of the CEO to the independent members of the Board for approval.
- Reviewing and approving the compensation of the Company's executive officers and key senior management, other than the CEO.
- Supervising the administration of the Company's equity incentive plans and approving equity compensation awards pursuant to these plans.
- Overseeing the management of risks related to the Company's executive and overall compensation, benefits plans, practices and policies.
- Maintaining direct responsibility for the appointment, compensation and oversight of the work of any compensation consultant, legal counsel or other external adviser retained by the Committee.

**AUDIT COMMITTEE**

Chair: Michael R. Dougherty

Other Committee Members: Adam M. Koppel, M.D., Ph.D. (until 10/1/18), Barbara Yanni, Scott Braunstein, M.D. (beginning 10/1/2018)

Meetings Held in 2018: 4

Primary Responsibilities:

- Evaluating the performance, objectivity, independence and qualifications of, and retaining or terminating the engagement of, Trevena's independent registered public accounting firm.
- Representing and assisting the Board in fulfilling its oversight responsibilities regarding the adequacy and effectiveness of internal controls, including financial and disclosure controls and procedures, and the quality and integrity of the Company's financial statements.
- Reviewing with management and the independent registered public accounting firm annual and quarterly financial statements, earnings releases, earnings guidance and significant accounting policies.
- Overseeing compliance with material legal and regulatory requirements.
- Overseeing the Company's enterprise risk management program and advising the Board on financial and enterprise risks.
- Maintaining procedures for and reviewing the receipt, retention and treatment of complaints regarding accounting, internal accounting controls, or auditing matters and the confidential, anonymous submissions by employees and others of any concerns about questionable accounting and auditing matters.

Financial Expertise and Financial Literacy:

The Board has determined that Mr. Dougherty is an audit committee financial expert as defined in the SEC rules, and all members of the Audit Committee are financially literate within the meaning of the Nasdaq listing standards.

Table of Contents

**DIRECTOR INDEPENDENCE**

The current Board includes eight non-employee directors, including the Company's former CEO, Maxine Gowen, Ph.D. To be independent under Nasdaq listing standards, the Board must affirmatively determine that a director has no material relationships with the Company directly, or as an officer, stockholder or partner of an organization that has a relationship with the Company (a Material Relationship). In making its assessment, the Board considers all relevant facts and circumstances, including whether transactions with such organizations are in the ordinary course of Trevena's business and/or the amount of such transactions (in aggregate or as a percentage of the organization's revenues or assets). The Board also considers that the Company may sell products and services to, and/or purchase products and services from, organizations affiliated with our directors and may hold investments (generally, debt securities) in organizations affiliated with our directors. On an annual basis, the Board, through its Nominating and Corporate Governance Committee, reviews relevant relationships between directors, their immediate family members and the Company, consistent with Trevena's independence standards. Trevena's standards, which are detailed in Trevena's Corporate Governance Guidelines available at [investors.trevena.com/corporate-governance](http://investors.trevena.com/corporate-governance), conform to the independence requirements set forth in the Nasdaq's listing standards.

The Board consults with our counsel to ensure that the Board's determinations are consistent with relevant securities and other laws and regulations regarding the definition of independent, including those set forth in pertinent Nasdaq listing standards.

Based on its review of director relationships, the Board has affirmatively determined that, with the exception of Dr. Gowen, the Company's former CEO, there are no Material Relationships between the non-employee directors and the Company and each of the non-employee directors, except for Dr. Gowen, is independent as defined in both the Nasdaq listing standards (including those applicable to certain board committees) and Trevena's director independence standards.

**CODE OF ETHICS**

Trevena is committed to integrity, legal compliance and ethical conduct. All directors and employees, including our executive officers, must comply with the Company's Code of Business Conduct and Ethics. The Code of Business Conduct and Ethics and Trevena's related policies and procedures address major areas of professional conduct, including, among others, conflicts of interest, protection of private, sensitive or confidential information, employment practices, insider trading and adherence to laws and regulations affecting the conduct of Trevena's business. The Code of Business Conduct and Ethics is available on our website at [investors.trevena.com/corporate-governance](http://investors.trevena.com/corporate-governance).

The Code of Business Conduct and Ethics requires all directors and employees to avoid any conflict or potential conflict between their personal interests (including those of their significant others and immediate family) and the best interests of the Company. Any conflict or potential conflict must be brought to the attention of the Compliance Officer for review and disposition. In addition, directors and officers cannot participate in a personal transaction with Trevena without first notifying and obtaining the approval of Audit Committee in accordance with the Company related person transaction policy described below.

**CERTAIN TRANSACTIONS**



**Transactions with Related Persons**

Trevena has adopted a written policy that sets forth our procedures for the identification, review, consideration and approval or ratification of related person transactions. For purposes of our policy only, a related person transaction is a transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we and any related person are, were or will be participants in which the amount involved exceeds \$120,000. Transactions involving compensation for services provided to us as an employee or director are not covered by this policy. A related person is any executive officer, director or beneficial owner of more than 5% of any class of our voting securities, including any of their immediate family members and any entity owned or controlled by such persons.

Table of Contents

Under the policy, if a transaction has been identified as a related person transaction, including any transaction that was not a related person transaction when originally consummated or any transaction that was not initially identified as a related person transaction prior to consummation, our management must present information regarding the transaction to our Audit Committee, or, if Audit Committee approval would be inappropriate, to another independent body of our Board of Directors, for review, consideration and approval or ratification. The presentation must include a description of, among other things, the material facts, the interests, direct and indirect, of the related persons, the benefits to us of the transaction and whether the transaction is on terms that are comparable to the terms available to or from, as the case may be, an unrelated third party or to or from employees generally. Under the policy, we will collect information that we deem reasonably necessary from each director, executive officer and, to the extent feasible, significant stockholder to enable us to identify any existing or potential related-person transactions and to effectuate the terms of the policy. In addition, under our Code of Business Conduct and Ethics, our employees and directors have an affirmative responsibility to disclose any transaction or relationship that reasonably could be expected to give rise to a conflict of interest. In considering related person transactions, our Audit Committee, or other independent body of our Board of Directors, will take into account the relevant available facts and circumstances including, but not limited to:

- the risks, costs and benefits to us;
- the impact on a director's independence in the event that the related person is a director, immediate family member of a director or an entity with which a director is affiliated;
- the availability of other sources for comparable services or products; and
- the terms available to or from, as the case may be, unrelated third parties or to or from employees generally.

The policy requires that, in determining whether to approve, ratify or reject a related person transaction, our Audit Committee, or other independent body of our Board of Directors, must consider, in light of known circumstances, whether the transaction is in, or is not inconsistent with, our best interests and those of our stockholders, as our Audit Committee, or other independent body of our Board of Directors, determines in the good faith exercise of its discretion.

Based on this review, there are no related person transactions requiring disclosure under SEC rules.

**Compensation Committee Interlocks and Insider Participation**

None of our directors who currently serve as members of our Compensation Committee is, or has at any time during the past year been, one of our officers or employees. None of our executive officers currently serves, or in the past year has served, as a member of the Board of Directors or Compensation Committee of any other entity that has one or more executive officers serving on our Board of Directors or Compensation Committee.

Table of Contents

PROPOSAL 1. ELECTION OF DIRECTORS

The Board of Directors is elected by Trevena's stockholders and is divided into three classes, each with a three-year term. There are currently nine members of the Board. Vacancies on the Board may be filled only by persons elected by a majority of the remaining directors. A director elected by the Board to fill a vacancy in a class, including vacancies created by an increase in the number of directors, shall serve for the remainder of the full term of that class and until the director's successor is duly elected and qualified.

At the Annual Meeting, the Board is nominating for election by stockholders three Class III directors, each of whom currently is a director of the Company. If elected at the Annual Meeting, each of these nominees would serve until the 2022 Annual Meeting of Stockholders and until her or his successor has been duly elected and qualified, or, if sooner, until the director's death, resignation, or removal.

The role of the Board, its leadership structure and governance practices are described above in the Corporate Governance section. This section describes the process for director elections and director nominations, identifies the director responsibilities and qualifications considered by the Board and the Nominating and Corporate Governance Committee in selecting and nominating directors, and presents the biographies, skills and qualifications of the director nominees and those directors continuing in office.

**PROCESS FOR SELECTING AND NOMINATING DIRECTORS**

The Nominating and Corporate Governance Committee may retain a third-party search firm to assist in identifying and evaluating candidates for Board membership. The Nominating and Corporate Governance Committee also considers suggestions for Board nominees submitted by stockholders, which are evaluated using the same criteria as new director candidates and current director nominees. Instructions for how to submit stockholder nominations to the Board can be found on page 38.

Once a potential candidate has been identified, the Nominating and Corporate Governance Committee reviews the background of new director candidates and presents them to the Board for consideration before selection. When considering director candidates and the current composition of the Board, the Nominating and Corporate Governance Committee and the Board consider how each candidate's background, experiences, skills, prior board and committee service and/or commitments will contribute to the diversity of the Board. Candidates interview with the Chair of the Nominating and Corporate Governance Committee and the Chairman of the Board, as well as other members of the Board, as appropriate. The Nominating and Corporate Governance Committee believes that candidates for director should have certain minimum qualifications, including the ability to read and understand basic financial statements, being over 21 years of age and having strong personal and professional ethics, integrity and values. The Nominating and Corporate Governance Committee also intends to consider additional criteria as follows: relevant expertise upon which to be able to offer advice and guidance to management; sufficient time to devote to the affairs of the Company; demonstrated excellence in his or her field; the ability to exercise sound business judgment; diversity; the commitment to rigorously represent the long-term interests of our stockholders; and independence. In addition, the Board and the Nominating and Corporate Governance Committee will consider the talents, ages, skills, diversity, experience, expertise and such other factors as appropriate given the current needs of the Board and the Company to maintain an appropriate and effective balance of knowledge, experience and capability on the Board as a whole.

The Nominating and Corporate Governance Committee assesses the Board's composition as part of the annual evaluation of the Board. When considering whether to nominate current directors for re-election, the Nominating and Corporate Governance Committee and the Board review the results of the annual evaluation and the qualifications, characteristics, skills and experience that it believes are important for representation on the Board. The Nominating and Corporate Governance Committee and the Board take into consideration these criteria for Trevena directors

## Edgar Filing: TREVENA INC - Form DEF 14A

as part of the director recruitment, selection, evaluation, and nomination process. While the Board does not have a formal policy with regard to diversity, the Nominating and Corporate Governance Committee and the Board strive to ensure that the Board is composed of individuals who together possess a breadth and depth of experience relevant to the Board's oversight of Trevena's business and strategy.

Table of Contents

**BOARD OF DIRECTORS NOMINEES**

Upon the recommendation of the Nominating and Corporate Governance Committee, the Board is nominating the three Class III directors listed below for re-election for terms expiring at the 2022 Annual Meeting of Stockholders. All nominees have consented to serve, and the Board does not know of any reason why any nominee would be unable to serve. If a nominee becomes unavailable or unable to serve before the Annual Meeting, the Board may reduce its size or designate another nominee. If the Board designates a nominee, your proxy will be voted for the substitute nominee.

Below are biographies, skills and qualifications for each of the nominees and for each of the directors continuing in office. Each of the director nominees currently serves on the Board. The Board believes that the combination of the various experiences, skills and qualifications represented contributes to an effective and well-functioning Board and that the nominees and directors continuing in office possess the qualifications, based on the criteria described above, to provide meaningful oversight of Trevena's business and strategy.

**The Board of Directors unanimously recommends that stockholders vote FOR the nominees listed below.**

**Scott Braunstein, M.D.**

**Independent**

**Director Since: 2018**

**Age: 55**

**Board Committee(s):**

- **Audit**

Dr. Braunstein currently is an Operating Partner at Aisling Capital Management LP, where he has served since 2015, and, since February 2019, is the Executive Chairman of Marinus Pharmaceuticals, Inc. (Marinus). From 2015 to 2018, Dr. Braunstein also served as Chief Operating Officer, SVP of Corporate Strategy, and Chief Strategy Officer at Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company. From 2014 to 2015, Dr. Braunstein served as a healthcare portfolio manager at Everpoint Asset Management. For twelve years prior to joining Everpoint, Dr. Braunstein was with J.P. Morgan Asset Management as a healthcare analyst and managing director in the U.S. Equity team and served as the portfolio manager for the J.P. Morgan Global Healthcare fund. Dr. Braunstein was responsible for managing investments in pharmaceuticals, biotechnology, and medical devices. Dr. Braunstein is currently Chairman of the Board of Directors for ArTara Therapeutics, Inc., and is a member of the Board of Directors of Esperion Therapeutics, Inc., Marinus, SiteOne Therapeutics, Inc., and Ziopharm Oncology, Inc. Dr. Braunstein began his career as a practicing physician at the Summit Medical Group and as Assistant Clinical Professor at Albert Einstein College of Medicine and Columbia University Medical Center. He earned his medical degree from the Albert Einstein College of Medicine.

**Skills and Qualifications**

Our Board believes that Dr. Braunstein's strategic insight, extensive experience as both a pharmaceutical company executive and an investor in healthcare companies, and knowledge as a physician allow him to make valuable contributions to the Board.



Table of Contents

**Leon (Lonnie) O. Moulder, Jr.**

**Independent Chairman of the Board** Mr. Moulder has served as Chairman of our Board since June 2013. From May 2010 to January 2019, Mr. Moulder was the co-founder, Chief Executive Officer and a member of the board of directors of TESARO, Inc., a public oncology-focused biopharmaceutical company that was acquired by GlaxoSmithKline plc. From April 2009 to January 2010, Mr. Moulder served as Vice Chairman of the board of directors, President and Chief Executive Officer of Abraxis BioScience, Inc., a biotechnology company. Before that, Mr. Moulder served as Vice Chairman of Eisai Corporation of North America, a pharmaceutical company and wholly owned subsidiary of Eisai Co., Ltd., from January 2008 until January 2009, following Eisai Co., Ltd.'s acquisition of MGI PHARMA, Inc., a pharmaceutical company in January 2008. Mr. Moulder served as President and Chief Executive Officer and as a member of the board of directors of MGI PHARMA, Inc. from May 2003 to January 2008. Mr. Moulder earned a bachelor of science degree in pharmacy from Temple University and a master of business administration degree from the University of Chicago. Mr. Moulder is a Trustee of Temple University and serves on the board of the Fox Chase Cancer Center. He also served as a director of Cubist Pharmaceuticals, Inc. from February 2010 until January 2015.

**Director Since: 2011**

**Age: 61**

**Board Committee(s):**

- **Compensation**

**Skills and Qualifications**

Our Board believes that Mr. Moulder's significant operational and senior management experience in the biopharmaceutical industry, as well as his extensive experience as a director on public and private boards in the industry, allow him to make valuable contributions to the Board.

**Michael R. Dougherty**

**Independent** Mr. Dougherty was Executive Chairman of Celator Pharmaceuticals, Inc., from August 2015 until July 2016; he also served as a director of Celator from July 2013 to July 2016. Previously, Mr. Dougherty was Chief Executive Officer and a member of the board of directors of Kalidex Pharmaceuticals, Inc., from May 2012 to October 2012. Mr. Dougherty was the President and Chief Executive Officer and a member of the board of directors of Adolor Corporation, a biopharmaceutical company, from December 2006 until December 2011. Mr. Dougherty joined Adolor in November 2002, and until his appointment as President and Chief Executive Officer in December 2006, served in a number of capacities, including Chief Operating Officer and Chief Financial Officer. From November 2000 to November 2002, Mr. Dougherty was President and Chief Operating Officer of Genomics Collaborative, Inc. Previously, Mr. Dougherty served in a variety of senior positions at Genaera Corporation, a biotechnology company, including as President and Chief Executive Officer and a member of the board of directors, and at Centocor, Inc. Mr. Dougherty is currently on the board of directors at Marinus Pharmaceuticals, Inc. Mr. Dougherty previously served as a member of the board of directors of Foundation Medicine, Inc., Aviragen Therapeutics, Inc., Cemptra, Inc., and ViroPharma Incorporated. Mr. Dougherty received a B.S. in Accounting from Villanova University.

**Director Since: 2013**

**Age: 61**

**Board Committee(s):**

- **Audit (Chair)**

**Skills and Qualifications**

Our Board believes that Mr. Dougherty's deep understanding of biotechnology finance, research and development, sales and marketing, strategy and operations enable him to make valuable contributions to the Board.



Table of Contents

**CLASS I DIRECTORS WHO WILL CONTINUE IN OFFICE UNTIL THE 2020 ANNUAL MEETING**

**Carrie L. Bourdow**

**Management**

Ms. Bourdow was appointed President, Chief Executive Officer, and member of our Board of Directors in October 2018. She joined our company as our Senior Vice President and Chief Commercial Officer in May 2015 and was appointed Executive Vice President and Chief Operating Officer in January 2018. From May 2013 to May 2015, she was Vice President of Marketing at Cubist Pharmaceuticals, Inc. Prior to joining Cubist in 2013, Ms. Bourdow served for more than 20 years at Merck & Co., Inc., where she held positions of increasing responsibility across several therapeutic areas including anti-infectives, acute heart failure, and pain. Ms. Bourdow has served as a director of Nabriva Therapeutics PLC since June 2017. Ms. Bourdow earned her B.A. from Hendrix College and her M.B.A. from Southern Illinois University.

**Director Since: 2018**

**Age: 56**

**Skills and Qualifications**

**Board Committee(s):**

- **None**

Our Board believes that Ms. Bourdow's knowledge of our company and her nearly 30 years of experience in the pharmaceutical industry, including high-level commercial roles at Merck and Cubist, provide a strong basis for her to make valuable contributions to the Board.

**Anne M. Phillips, M.D.**

**Independent**

**Director Since: 2014**

**Age: 65**

Dr. Phillips currently is Senior Vice President of Clinical, Medical and Regulatory Affairs at Novo Nordisk Inc., a pharmaceutical company, where she has served since 2011. Previously, she served as a Vice President in various positions at GlaxoSmithKline plc, which she joined in 1998, and prior to this Dr. Phillips was Head of the Infectious Diseases Program and Deputy Physician-in-Chief at Wellesley Central Hospital/St. Michael's Hospital in Toronto, Canada. She is a Fellow of The Royal College of Physicians and Surgeons of Canada, earned an MD from the University of Toronto and received a BSc from the University of Western Ontario.

**Skills and Qualifications**

**Board Committee(s):**

- **Nominating and Corporate Governance**

Our Board believes that Dr. Phillips' extensive late-stage clinical development experience in well-established pharmaceutical companies, together with her significant experience and knowledge as a physician, positions her to make valuable contributions to the Board.

- **Compensation**



Table of Contents

**Barbara Yanni**

**Independent**

**Director Since: 2014**

**Age: 64**

Ms. Yanni was Vice President and Chief Licensing Officer at Merck & Co., a pharmaceutical company, from November 2001 until her retirement in March 2014. Prior to this, Ms. Yanni served in various roles at Merck including in corporate development, financial evaluation, and tax. Ms. Yanni has served on the Board of Directors of Vaccinex, Inc. and Cerenus Therapeutics, SA, both public biotechnology companies, since 2015 and 2018, respectively. She also serves on the board of directors of Symic Holdings, LLC, a private biotechnology company. Ms. Yanni earned a J.D. from Stanford Law School and an A.B. from Wellesley College. She also holds a Masters of Law in Taxation from New York University.

**Board Committee(s):**

**Skills and Qualifications**

- **Audit**
- **Compensation (Chair)** Our Board believes that Ms. Yanni's extensive experience in biotechnology and pharmaceutical business evaluation and transaction execution, as well as her financial and general business knowledge allow her to make significant contributions to the Board.

**CLASS II DIRECTORS WHO WILL CONTINUE IN OFFICE UNTIL THE 2021 ANNUAL MEETING**

**Maxine Gowen, Ph.D.**

**Non-Independent**

**Director Since: 2007**

**Age: 61**

**Board Committee(s):**

- **None**

Dr. Gowen is the founder of Trevena and served as its President and Chief Executive Officer from 2007 until October 2018. Prior to this Dr. Gowen held a variety of leadership roles at GlaxoSmithKline (GSK) over a period of fifteen years. As Senior Vice President for the Center of Excellence for External Drug Discovery (CEEDD), she developed an innovative new approach to externalizing drug discovery in big pharma. Dr. Gowen was previously President and Managing Partner at SR One, the venture capital subsidiary of GSK, where she led its investments in and served on the board of directors of numerous companies. Until 2002 Dr. Gowen was Vice President, Drug Discovery, Musculoskeletal Diseases at GSK, responsible for drug discovery and early development for osteoporosis, arthritis and metastatic bone disease. Dr. Gowen held a tenured academic position in the School of Pharmacology, University of Bath, UK from 1989-1992. She has authored more than 100 refereed scientific publications. Dr. Gowen graduated with a B.Sc. in biochemistry from the University of Bristol, UK, then received a Ph.D. in cell biology from the University of Sheffield, UK, and received an MBA from the Wharton School of the University of Pennsylvania. Dr. Gowen served on the board of Human Genome Sciences (HGSI) until its purchase by GSK in July 2012. She currently serves on the board of Akebia Therapeutics, Inc. since July 2014 and Idera Pharmaceuticals, Inc. since January 2016, both public biopharmaceutical companies, and on the board of the state biotechnology industry association, Life Sciences PA. Dr. Gowen also served on the board of the national biotechnology industry association, BIO, from 2008 to 2018.

**Skills and Qualifications**

Our Board believes that Dr. Gowen's past leadership of our company and her over 25 years in the pharmaceutical industry, including her roles at GSK, provide a critical contribution to the Board.

Table of Contents

**Julie H. McHugh**

**Independent**

Ms. McHugh was Chief Operating Officer of Endo Health Solutions Inc., a global specialty healthcare company, from March 2010 to May 2013, and since May 2013 she has provided consulting services to companies in the pharmaceuticals industry. Prior to that, from September 2008 to September 2009, she served as Chief Executive Officer of Nora Therapeutics, Inc., a private biotechnology company. From 2006 to 2008 she was Company Group Chairman for Johnson & Johnson's worldwide virology business unit and from 2004 to 2006 she was President of Centocor, Inc., a Johnson & Johnson subsidiary. Ms. McHugh has served on the boards of directors of Ironwood Pharmaceuticals, Inc., Aerie Pharmaceuticals, Inc., and Lantheus Holdings, Inc. all public pharmaceutical companies, since February 2014, June 2015, and January 2017, respectively. Ms. McHugh also serves on the board of directors of Xellia Pharmaceuticals AS, a private specialty pharmaceutical company.

**Director Since: 2014**

**Age: 54**

**Board Committee(s):**

- **Nominating and Corporate Governance (Chair)**

**Skills and Qualifications**

Our Board believes that Ms. McHugh's deep knowledge of biotechnology strategy, operations, research and development, and sales and marketing allows her to make valuable contributions to the Board.

**Jake R. Nunn**

**Independent**

Mr. Nunn is currently a venture advisor at New Enterprise Associates, Inc., a venture capital firm, where he was a Partner from June 2006 until January 2019. From January 2001 to June 2006, Mr. Nunn served as a Partner and an analyst for the MPM BioEquities Fund, a life sciences fund at MPM Capital, L.P., a private equity firm. Previously, Mr. Nunn was a healthcare research analyst and portfolio manager at Franklin Templeton Investments and an investment banker with Alex. Brown & Sons. Mr. Nunn currently serves on the board of directors of Dermira, Inc. and Addex Therapeutics Ltd., both public biopharmaceutical companies. Mr. Nunn received his A.B. in economics from Dartmouth College and his M.B.A. from the Stanford Graduate School of Business. Mr. Nunn also holds the Chartered Financial Analyst designation, and is a member of the C.F.A. Society of San Francisco.

**Director Since: 2013**

**Age: 48**

**Board Committee(s):**

- **Nominating and Corporate Governance**

**Skills and Qualifications**

Our board of directors believes that Mr. Nunn's experience investing in life sciences, specialty pharmaceuticals, biotechnology and medical device companies, as well as his business and financial background, qualify him to serve on our board of directors.

Table of Contents

NON-EMPLOYEE DIRECTOR COMPENSATION

**OVERVIEW**

The Compensation Committee reviews and makes recommendations to the Board about the compensation paid to non-employee directors for service on the Trevena Board of Directors. A director who also is an employee of the Company does not receive payment for services as a director. The CEO is the only employee who currently serves as a director.

The Board believes that the current director compensation program:

- aligns with stockholder interests because it includes a significant equity-based compensation component, the value of which is tied to Trevena's stock price; and
- is competitive based on the work required of directors serving on the board of an entity of the Company's size, complexity and scope.

The Compensation Committee's charter provides that it will periodically review director compensation and recommend any changes to the Board for its approval. The Compensation Committee may from time to time engage an independent compensation consultant to assist in its review of director compensation.

**DIRECTOR COMPENSATION PROGRAM**

In December 2015, after consultation with Trevena's independent compensation consultant, the Board approved the non-employee director compensation program set forth below, effective as of January 1, 2016. This program remained in effect until February 2018. In February 2018, after consultation with Trevena's independent compensation consultant, the Board approved an increase in the number of options awarded to a non-employee director upon initial election to the Board and annually at the Annual Meeting of Stockholders, as reflected below. All aspects of the program related to cash compensation for non-employee directors remained unchanged.

**Annual Cash Compensation**

The following chart summarizes the retainer compensation provided to non-employee directors for their ongoing service on the Trevena Board during 2018. Cash payments are made in equal, quarterly installments.

<b>Retainer Type</b>	<b>Annual Amount</b>
Board member	\$ 35,000
Committee member	
• Audit	\$ 7,500
• Compensation	\$ 5,000
• Nominating and Corporate Governance	\$ 5,000
Committee chair (in lieu of Committee Member fee)	
• Audit	\$ 15,000
• Compensation	\$ 10,000
• Nominating and Corporate Governance	\$ 8,000

In addition to the Board annual retainer, the Chairman of the Board receives a \$30,000 cash retainer for his service as Chairman.

### **Equity Compensation**

The equity compensation awards to non-employee directors are made under the 2013 Equity Incentive Plan, as amended (the 2013 Equity Plan). All stock options granted to directors will be nonstatutory stock options, with an exercise price per share equal to 100% of the fair market value (as defined in the 2013 Equity Plan) of the underlying common stock on the date of grant, and a term of ten years from the date of grant (subject to earlier termination in connection with a termination of service as provided in the 2013 Equity Plan).

Table of Contents

- Initial Grant.** On the date of the non-employee director's initial election or appointment to the Board, such non-employee director will be granted a stock option for 60,000 shares, subject to appropriate adjustment for any stock split, stock dividend, reverse stock split, stock combination or other change in our capitalization. Commencing on the first date that is three months after the date of grant, the shares subject to each stock option will vest in a series of 12 equal quarterly installments, such that the option is fully vested on the third anniversary of the date of grant, subject to the non-employee director's continuous service through each such vesting date; provided that the vesting date for the quarterly period in which our annual stockholders' meeting occurs shall be the date immediately prior to such annual meeting.
- Annual Grant.** On the date of the Company's 2018 annual stockholder meeting, each non-employee director who continued to serve as a non-employee director member of the Board immediately thereafter was granted a stock option for 30,000 shares, subject to appropriate adjustment for any stock split, stock dividend, reverse stock split, stock combination or other change in our capitalization. The shares subject to the stock option will vest on the day immediately prior to the next annual stockholders' meeting held after the date of grant, subject to the non-employee director's continuous service through such vesting date.

**DIRECTOR COMPENSATION TABLE FOR 2018**

The table below includes information about the compensation paid to non-employee directors in 2018. Dr. Gowen served as the Company's President and CEO until her retirement on October 1, 2018 and did not receive any director compensation for her Board service prior to this date. Dr. Gowen's compensation is set forth under "Executive Compensation" 2018 Summary Compensation Table.

Name	Fees Earned or Paid in Cash (\$)	Option Awards(1) (\$)	Total Compensation (\$)
Scott Braunstein, M.D.(2)	10,625	88,663	99,288
Michael R. Dougherty	50,000	30,856	80,856
Adam M. Koppel, M.D., Ph.D.(2)	21,250	30,856	52,106
Julie H. McHugh	43,000	30,856	73,856
Leon O. Moulder, Jr.	70,000	30,856	100,836
Jake R. Nunn	40,000	30,856	70,856
Anne M. Phillips, M.D.	45,000	30,856	75,856
Barbara Yanni	52,500	30,856	83,356

(1) At December 31, 2018, the aggregate number of stock option awards outstanding for each non-employee director was as follows: Dr. Braunstein, 88,663; Mr. Dougherty, 95,481; Ms. McHugh, 86,611; Mr. Moulder, 89,836; Mr. Nunn, 77,740; Dr. Phillips, 86,611; and Ms. Yanni, 86,611.

(2) Dr. Braunstein joined the Board, effective as of September 27, 2018. Dr. Koppel resigned from the Board, effective as of October 1, 2018.



Fees Earned or Paid in Cash

- Represents cash compensation for the retainers described above for the period January 31, 2018 to December 31, 2018.
- In 2018, Mr. Moulder served as Chairman of the Board, Mr. Dougherty served as Audit Committee chair, Ms. McHugh served as Nominating and Governance Committee chair, and Ms. Yanni served as Compensation Committee chair.

Option Awards

This column lists the aggregate grant date fair value of options awarded to directors pursuant to the non-employee director compensation program, computed in accordance with FASB Accounting Standards Codification (ASC) Topic 718, applying the same model and assumptions that Trevena applies for financial statement reporting purposes as described in Note 7 to Trevena's financial statements contained in its Annual Report on Form 10-K for the year ended December 31, 2018 (disregarding any estimates for forfeitures).

Table of Contents

PROPOSAL 2. RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS

The Audit Committee is directly responsible for the appointment, compensation, retention and oversight of the independent registered public accounting firm retained to audit the Company's financial statements. The Audit Committee approved the appointment of Ernst & Young LLP as Trevena's independent registered public accounting firm for the fiscal year ending December 31, 2019. Ernst & Young LLP has served as Trevena's independent registered public accounting firm since 2007. To assure continuing auditor independence, the Audit Committee periodically considers whether there should be a regular rotation of the independent registered public accounting firm. Further, in conjunction with the mandated rotation of the audit firm's lead engagement partner, the Chair of the Audit Committee discusses with Ernst & Young LLP the selection of the new lead engagement partner.

The Audit Committee and the Board believe that the continued retention of Ernst & Young LLP to serve as the Company's independent registered public accounting firm is in the best interests of the Company and its stockholders. As a matter of good corporate governance, the Board is seeking stockholder ratification of the appointment even though ratification is not legally required. If stockholders do not ratify this appointment, the Audit Committee will reconsider Ernst & Young LLP's appointment. Even if the selection is ratified, the Audit Committee in its discretion may select a different independent registered public accounting firm at any time of the year if it determines that such a change would be in the best interests of the Company and its stockholders.

A representative from Ernst & Young LLP is expected to attend the Annual Meeting, may make a statement, and will be available to respond to appropriate questions.

**The Board of Directors unanimously recommends that stockholders vote FOR the ratification of the appointment of Ernst & Young LLP as Trevena's independent registered public accounting firm for the fiscal year ending December 31, 2019 as set forth in this Proposal 2.**

**Policy for the Pre-Approval of Audit and Permissible Non-Audit Services**

The Audit Committee pre-approves all audit and permissible non-audit services provided by the Company's independent registered public accounting firm, Ernst & Young LLP, pursuant to a written policy. Under the pre-approval policy, the Audit Committee pre-approves specified services in the defined categories of audit services, audit-related services, and tax services up to specified amounts. Pre-approval may also be given as part of the Audit Committee's approval of the scope of the engagement of the independent registered public accounting firm or on an individual explicit case-by-case basis before the independent registered public accounting firm is engaged to provide each service. The pre-approval of services may be delegated to one or more of the Audit Committee's members, but the decision must be reported to the full Audit Committee at its next scheduled meeting.

The Audit Committee has determined that the rendering of the services below by Ernst & Young LLP is compatible with maintaining the principal accountant's independence.



Table of Contents**Fees to Independent Registered Public Accounting Firm**

Aggregate fees billed for professional services rendered by Ernst & Young LLP for the audit of financial statements for the fiscal years ended December 31, 2018 and December 31, 2017, and fees billed for other services rendered by Ernst & Young LLP during those periods were as follows:

	2018		2017
Audit Fees	\$ 477,740	\$	390,000
Audit-Related Fees	2,000		2,000
Tax Fees	12,000		10,812
All Other Fees			
<b>TOTAL</b>	<b>\$ 491,740</b>	<b>\$</b>	<b>402,812</b>

- *Audit fees* include fees incurred for professional services rendered for the audit of our annual financial statements, the review of quarterly financial statements, filing of registration statements and delivery of auditor comfort letters.
- *Audit-related fees* include assurance and related services that were reasonably related to the audit of annual financial statements and reviews of quarterly financial statements, but not reported under Audit Fees. For 2018 and 2017, audit-related fees consisted of access to Ernst & Young LLP's proprietary accounting database.
- *Tax fees* include fees incurred in connection with tax advice and tax planning. These services included assistance with tax reporting requirements and audit compliance.

Table of Contents

REPORT OF THE AUDIT COMMITTEE

Trevena maintains an independent Audit Committee that operates under a written charter adopted by the Board of Directors. The Audit Committee's charter is available on our website at [investors.trevena.com/corporate-governance](http://investors.trevena.com/corporate-governance). All of the members of the Audit Committee are independent (as defined in the listing standards of Nasdaq and SEC regulations).

Trevena's management has primary responsibility for preparing Trevena's financial statements and establishing and maintaining financial reporting systems and internal controls. Management also is responsible for reporting on the effectiveness of Trevena's internal control over financial reporting. The independent registered public accounting firm is responsible for performing an independent audit of Trevena's financial statements and issuing a report on these financial statements. As provided in the Audit Committee's charter, the Audit Committee's responsibilities include oversight of these processes.

In this context, before Trevena filed its Annual Report on Form 10-K for the year ended December 31, 2018 (Form 10-K) with the SEC, the Audit Committee:

- Reviewed and discussed with Trevena's management the audited financial statements included in the Form 10-K and considered management's view that the financial statements present fairly, in all material respects, the financial condition and results of operations of Trevena.
- Reviewed and discussed with Trevena's management and with the independent registered public accounting firm, Ernst & Young LLP, the effectiveness of Trevena's internal control over financial reporting as well as management's report on the subject.
- Discussed with Ernst & Young LLP, matters related to the conduct of its audit that are required to be communicated by auditors to audit committees and matters related to the fair presentation of Trevena's financial condition and results of operations, including critical accounting estimates and judgments.
- Received the required communications from Ernst & Young LLP that disclose all relationships that may reasonably be thought to bear on its independence and to confirm its independence. Based on these communications, the Audit Committee discussed with Ernst & Young LLP its independence from Trevena.
- Discussed with each of Trevena's Chief Executive Officer and Principal Financial Officer their required certifications contained in Trevena's Form 10-K.

## Edgar Filing: TREVENA INC - Form DEF 14A

Based on the foregoing, the Audit Committee recommended to the Board of Directors that such audited financial statements be included in Trevena's Annual Report on Form 10-K for the year ended December 31, 2018 for filing with the SEC.

### **AUDIT COMMITTEE:**

Michael R. Dougherty, Chair  
Scott Braunstein, M.D.  
Barbara Yanni

*The material in this report is not soliciting material, is not deemed filed with the SEC and is not to be incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.*

Table of Contents

EXECUTIVE COMPENSATION

OVERVIEW

**Compensation Objectives and Practices**

Trevena's pay-for-performance compensation philosophy has the following key objectives:

- Align the interests of the Company's executives with those of its stockholders and reward the creation of long-term value for Trevena stockholders.
- Emphasize performance-based short-term and long-term compensation over fixed compensation.
- Motivate superior enterprise results with appropriate consideration of risk and while maintaining commitment to the Company's ethics and values.
- Reward the achievement of favorable long-term results more heavily than the achievement of short-term results.
- Provide market competitive compensation opportunities designed to attract, retain and motivate highly qualified executives.

To achieve these key objectives, the Compensation Committee uses the following compensation practices, processes and instruments:

- Annual pay-for-performance assessment by the Compensation Committee of the achievement of the Company's corporate goals and an individual executive officer's performance.
- A regular analysis of relevant market compensation data for each executive officer.

- Equity-based incentive plans (the 2013 Equity Plan and the Trevena, Inc. Inducement Plan) focused on longer-term stockholder value creation. For example, stock options generally vest over a four-year period, with awards vesting in equal, annual or quarterly installments from the date of grant.
- A cash-based incentive plan (the Trevena, Inc. Incentive Compensation Plan, or ICP) designed to motivate executive officers to achieve the Company's annual goals.
- The retention by the Compensation Committee of an independent compensation consultant to assist in the Committee's design and implementation of the Company's executive compensation programs.

In general, the Compensation Committee seeks to position the Company's compensation, target total cash compensation and long-term equity incentive compensation at the market 50th percentile. However, with respect to each component, the Company may choose to target compensation below or above (e.g., up to the market 75th percentile) based on an assessment of individual experience, scope of position, performance, potential and retention concerns, as applicable.

While the Company's Board of Directors has the ultimate responsibility for risk oversight, the Compensation Committee oversees compensation-related risks, including with respect to the Company's corporate objectives and overall compensation design and awards. Specifically, the Compensation Committee seeks to ensure that Trevena's compensation programs and policies do not encourage unnecessary or excessive risk-taking behavior by executives and do not create unreasonable risks.



Table of Contents

**Compensation Governance and Controls**

In implementing the compensation philosophy described above, the Compensation Committee regularly reviews market data, the composition of Trevena's peer group, as well as other items, in determining which pay elements to offer, the target pay mix, the design of our short- and long-term incentive plans and each executive officer's target total direct compensation.

The Compensation Committee also regularly reviews executive compensation governance market trends and strives to reflect the views of stockholders when considering the adoption of new practices or changes to existing programs or policies. Our governance practices and controls include:

- Double trigger requirement for change of control benefits.
- No tax gross-up of severance pay upon a change of control.
- Prohibition of hedging of Trevena stock by all directors and employees, including the executive officers.
- Prudent management of annual share usage (or burn rate) and total dilution under the 2013 Equity Plan.
- No executive officer perquisites.
- The Compensation Committee's ongoing review of the general long-term compensation strategy for the Company and assessments of executive officers and key senior management in connection with compensation decisions, and assistance to the Board of Directors in CEO and executive officer succession plans.
- The Compensation Committee's oversight of risk related to compensation programs and policies, including plan design features that mitigate the risk of incentive compensation having an unintended negative financial impact.

**Process for Executive Compensation Decisions**

**Use of External Data**

In September 2018, the Compensation Committee approved the list of companies to be included in the peer group in effect for use in 2018 year-end compensation decisions (the 2018 peer group). In developing the 2018 peer group, the Compensation Committee, with the assistance of its independent compensation consultant, identified similarly situated biopharmaceutical companies based on market capitalization, stage of development and number of employees, among other things.

For the 2018 year-end compensation decisions, the Compensation Committee established the Company's compensation for the executive officers based on a variety of factors, including a blend of (i) publicly available data from the 2018 peer group and (ii) published survey data for the life sciences industry and the 2018 peer group.

**Chief Executive Officer Compensation**

The Compensation Committee annually evaluates the CEO's performance and Trevena's performance against its pre-established goals and makes recommendations to the independent members of the Board of Directors about the CEO's performance and compensation. The Board then considers the Compensation Committee's recommendations as part of its review and approval of the CEO's compensation. The Chairman of the Board reviews the results of the evaluation with the CEO.

The CEO is not present when the Compensation Committee and the Board are making decisions about the CEO's compensation. The Company's internal legal counsel, head of human resources, and/or the independent compensation consultant attend meetings at the request of the Compensation Committee.

Table of Contents

**Other Executive Officer Compensation**

Generally, the CEO presents recommendations for the other executive officers' compensation targets for the Compensation Committee's consideration and approval. For compensation decisions involving actual payouts for the executive officers, the CEO presents her recommendations to the Compensation Committee for its consideration. The CEO discusses Trevena's performance and the individual officer's performance. The Company's internal legal counsel is generally present for the discussion of compensation for all executive officers other than himself.

**Compensation Consultant Role in Executive Compensation**

While the Compensation Committee or Board ultimately makes all executive compensation decisions, the Compensation Committee engages the services of outside advisors for assistance. In 2016, the Compensation Committee engaged Radford as its independent compensation consultant, and in 2017 and 2018, the Compensation Committee engaged Pearl Meyer as its independent compensation consultant.

The Compensation Committee utilized Pearl Meyer and Radford throughout these periods to provide independent, objective analysis, advice and information and to generally assist the Compensation Committee in the performance of its duties. The Compensation Committee will typically request information and recommendations directly from the compensation consultant as it deems appropriate to structure and evaluate Trevena's compensation programs, practices and plans. As part of its engagement, at the direction of the Compensation Committee, the compensation consultant will work, and exchange information, with the Company's internal legal counsel and the Company's head of human resources in their work on the Compensation Committee's behalf.

At the direction of the Compensation Committee, Pearl Meyer provided services to the Compensation Committee, including the following items:

- evaluated the effect of Trevena's equity program on annual share use, burn rate (the number of shares awarded per year divided by the shares outstanding at the end of the year) and total dilution (the number of stock options and restricted stock outstanding, plus the number of shares available for grants under the 2013 Equity Plan, divided by the total number of shares of common stock outstanding);
- presented a comparison of competitive market data to the current compensation of each Executive Officer to assist in setting compensation targets for 2018;
- presented an assessment of the compensation of the Company's CEO against Institutional Shareholder Services' CEO pay-for-performance test;

- reviewed the Executive Compensation section of the 2018 proxy statement; and
- reviewed the compensation program for the Company's non-employee directors.

**Independence of the Compensation Consultant**

The Compensation Committee assesses the compensation consultant's independence each year. In assessing independence, the Compensation Committee considers:

- the provision of other services to the Company by the consultant;
- the amount of fees paid to the consultant by the Company as a percentage of consultant's total revenue;
- the policies and procedures of the consultant's employer that are designed to prevent conflicts of interests;
- any business or personal relationship between the consultant and a member of the Compensation Committee;
- any Company stock owned by the consultant;
- any business or personal relationship of the consultant and an executive officer of the Company; and
- any other factor deemed relevant to the consultant's independence from management.

Table of Contents

In addition, each year the Compensation Committee receives a letter from its compensation consultant providing appropriate assurances and confirmation of independence. The Compensation Committee determined that Pearl Meyer was independent under applicable Nasdaq rules.

At the request of the Compensation Committee, a representative of Pearl Meyer attended all of the Compensation Committee's regularly scheduled meetings in 2018. The Compensation Committee annually reviews and evaluates its compensation consultant engagement and performance.

**2018 Executive Compensation Program**

Trevena's 2018 executive compensation program consists of the following elements:

Element	Description
<b>Base Salary</b>	Represents the fixed portion of each executive's total direct compensation package.
<b>Annual Cash Incentive</b>	At-risk compensation based on performance. Annual incentive awards under the ICP are based on the achievement of corporate results relative to pre-established goals, as adjusted for individual performance, accomplishments and contributions.
<b>Long-Term Incentives</b>	At-risk compensation based on individual performance. Trevena's long-term equity incentive program also is considered performance-based compensation. In accordance with Trevena's compensation strategy, the predominant portion of an executive's compensation opportunity is tied to the long-term success of the Company.
<b>Retirement Compensation</b>	Trevena provides retirement benefits that are aligned to competitive market practices, including a 401(k) plan for all full-time employees that provides for employee contributions as well as Company matching contributions of up to 4.0% of eligible pay.
<b>No Perquisites; Other Benefits</b>	Our executives do not receive any perquisites. However, they are eligible for all benefits offered to Trevena employees generally, including medical benefits, other health and welfare benefits, and other voluntary benefits.

**2018 SUMMARY COMPENSATION TABLE**

This table includes information regarding 2016, 2017, and 2018 compensation for each of our CEO (and former CEO) and our two other most highly compensated executive officers in 2018, which are referred to as the named executive officers, or NEOs. Other tables in this proxy statement provide more detail about specific types of compensation with respect to 2018.

Name and Principal Position	Year	Salary (\$)	Stock Awards (\$)	Non-Equity		All Other Compensation (\$)	Total (\$)
				Option Awards (\$)	Incentive Plan Compensation (\$)		
<b>Carrie L. Bourdow(1)</b> <i>President and Chief Executive Officer</i>	2018	418,314	162,500	1,041,309	146,719	11,073	1,779,915
	2017	341,169		606,868	130,413	10,800	1,089,250
	2016	330,417		520,534	116,025	10,600	977,575
<b>Mark A. Demitrack, M.D.(2)</b> <i>SVP and Chief Medical Officer</i>	2018	230,573	81,250	297,270	103,950	6,764	719,807

Edgar Filing: TREVENA INC - Form DEF 14A

<b>John M. Limongelli(3)</b>	2018	354,205	207,592	99,712	11,073	672,583
<i>SVP, General Counsel &amp; Chief</i>	2017	342,713	606,868	109,169	10,800	1,069,550
<i>Administrative Officer</i>	2016	330,333	650,667	116,550	10,600	1,108,151
<b>Maxine Gowen, Ph.D.(4)</b>	2018	431,650	780,843		944,435	2,156,929
<i>(Former) President and Chief</i>	2017	536,667	1,992,612	268,785	10,800	2,808,864
<i>Executive Officer</i>	2016	513,917	1,917,756	260,000	10,600	2,702,273

- 
- (1) Ms. Bourdow became Executive Vice President and Chief Operating Officer in January 2018 and President and Chief Executive Officer on October 1, 2018.
- (2) Dr. Demitrack joined the Company on May 21, 2018.
- (3) Mr. Limongelli resigned from the Company, effective on March 1, 2019.
- (4) Dr. Gowen retired from the Company on October 1, 2018.

Table of Contents

Base Salary

For Dr. Gowen, base salary includes \$8,750 paid for her service as a Board member in the fourth quarter of 2018, following her retirement as President and Chief Executive Officer of the Company.

Stock Awards

The amounts in this column represents the full grant date fair value as of December 6, 2018 of restricted stock unit awards made under the 2013 Equity Plan, computed in accordance with ASC Topic 718 applying the same model and assumptions as Trevena applies for financial statement reporting purposes, as described in Note 7 to Trevena's consolidated financial statements contained in its Annual Report on Form 10-K for the year ended December 31, 2018 (disregarding any estimates for forfeitures).

Option Awards

The amounts in this column represents the full grant date fair value of option awards made under the 2013 Equity Plan for 2018, 2017, and 2016, computed in accordance with ASC Topic 718 applying the same model and assumptions as Trevena applies for financial statement reporting purposes, as described in Note 7 to Trevena's consolidated financial statements contained in its Annual Report on Form 10-K for the year ended December 31, 2018 (disregarding any estimates for forfeitures). The value of Trevena stock option awards are determined using a Black-Scholes pricing methodology that assumes that all stock options are held to full-term (ten years). These amounts do not reflect the actual economic value that will be realized by the NEO upon the vesting of the stock options, the exercise of the stock options or the sale of the common stock underlying such stock options.

Non-Equity Incentive Plan Compensation

The ICP became effective as of January 1, 2015. Amounts in this column for 2018, 2017, and 2016 reflect awards made under the ICP for the 2018, 2017, and 2016 fiscal years, respectively, as discussed further under "Annual Cash Incentive" below.

All Other Compensation

This column includes Trevena's matching contributions to the NEOs' accounts under its 401(k) plan up to the maximum amount of \$11,000 for Ms. Bourdow, Mr. Limongelli, and Dr. Gowen, and \$6,764 for Dr. Demitrack. For Dr. Gowen, the amount also includes \$907,200 accrued in connection with her retirement from the Company, of which \$458,325 has been paid as of December 31, 2018, and \$26,162 for medical and dental premiums paid or payable on Dr. Gowen's behalf for the twelve months following her departure.

**NARRATIVE TO 2018 SUMMARY COMPENSATION TABLE**

**Annual Base Salary**

**Key Features**

- Base salary levels are set with reference to both:
- Competitive market data; and
- Individual performance.
- Base salary levels are reviewed annually during the performance review process and may be adjusted as a result of updated market data and an assessment of an executive's skills, role and performance contributions, including the demonstration of Trevena's leadership behaviors and core values. The overall salary budget also is a factor in determining the extent of base salary adjustments.

**Base Salary**

The table below presents the annual base salaries for the years 2016, 2017, and 2018 for each of our NEOs employed by the Company as of December 31, 2018. Salaries shown in 2016 and 2017 became effective on March 1, 2017 and March 1, 2018, respectively. Effective February 1, 2018, Ms. Bourdow's base salary was increased to \$385,000 in connection with her promotion to Executive Vice President and Chief Operating Officer. In connection with her appointment as President and Chief Executive Officer on October 1, 2018, her base salary was increased to \$500,000. In December 2018, Ms. Bourdow's salary was increased to \$550,000, effective as of



Table of Contents

January 1, 2019. Dr. Demitrack joined Trevena in May 2018 with a base salary of \$365,000, which was increased to \$440,000, effective as of December 1, 2018. Effective as of March 1, 2018, 2018, Dr. Gowen's base salary was increased to \$567,000, where it remained until her retirement on October 1, 2018. For 2018, the base salary for each of the NEOs was considered to be within the competitive range of market data provided to the Compensation Committee by Pearl Meyer.

Name	2016	2017	2018
Carrie L. Bourdow	\$ 331,500	\$ 343,103	\$ 500,000
Mark A. Demitrack, M.D.	n/a	n/a	\$ 440,000
John M. Limongelli	\$ 333,000	\$ 344,365	\$ 356,115
Maxine Gowen, Ph.D.	\$ 520,000	\$ 540,000	n/a

**Annual Cash Incentive****Key Features of the ICP**

Our ICP motivates and rewards our executives for achievements relative to both corporate and individual goals for each fiscal year. The ICP includes the following key features:

- Annual cash incentives (an Award) are primarily paid under the ICP. The Compensation Committee (or, as applicable, the Board) annually approves:
  - Corporate performance measures and goals;
  - Target bonus opportunity for each NEO, defined as a percentage of his or her annual salary;
  - Funding levels for actual ICP Awards; and
  - Individual Awards for the NEOs, except for the CEO's Award, which is approved by the Board.
- Annual Awards for each of the NEOs are generally targeted at the 50<sup>th</sup> percentile of the primary market reference.

- Subject to certain limits described below, the actual Award for an NEO will generally range from 0% to 150% of the individual's target and, if applicable, will be paid in the first quarter following the end of the performance year.

**Target Incentive Award Levels**

The Compensation Committee establishes the target cash incentive opportunity for each executive officer other than the CEO, and the Board establishes the target cash incentive opportunity for the CEO assuming full achievement against the Corporate Objectives and any individual objectives. For 2018, the target cash incentive opportunity for each of the NEOs was considered to be within the competitive range of market data provided to the Compensation Committee by Pearl Meyer. The following table shows the amount of the target incentive for each NEO as of December 31, 2018 as a percentage of salary over the past three years:

<b>Name</b>	<b>2016</b>	<b>2017</b>	<b>2018</b>
Carrie L. Bourdow	35%	35%	60%
Mark A. Demitrack, M.D.	n/a	n/a	40%
John M. Limongelli	35%	35%	40%
Maxine Gowen, Ph.D.	50%	55%	n/a

Table of Contents

The target incentive opportunity for Ms. Bourdow for 2018 was increased to 45% of base salary, effective as of February 1, 2018, in connection with her promotion to Executive Vice President and Chief Operating Officer and to 60% of base salary, effective as of October 1, 2018, in connection with her promotion to President and Chief Executive Officer. Effective March 1, 2018, the target incentive opportunities for Mr. Limongelli was increased to 40% of base salary. The target incentive opportunity for Dr. Gowen for 2018 was 60% of base salary until her retirement on October 1, 2018.

**ICP Corporate Goals, Weightings and Funding**

Effective January 1, 2015, the Board approved the adoption of the ICP. The ICP is designed to provide participants in the plan, including the Company's NEOs, with an incentive in the form of a cash Award to achieve specified corporate and individual objectives during a period of time selected by the Board to which the Award relates.

Each year, the Board, upon the recommendation of the Compensation Committee, establishes major corporate objectives for the coming fiscal year (and the relative weighting of such objectives) (the Corporate Objectives). The Board believes the Corporate Objectives will contribute to the long-term success of the Company by aligning with and driving the execution of the Company's business strategy. A minimum of 60% achievement against the Corporate Objectives is necessary for any Award payout under the ICP, and the maximum Award to any participant is 150% of the applicable target Award.

At the end of the fiscal year, the Board, upon the recommendation of the Compensation Committee, reviews and approves the level of the Company's achievement against the Corporate Objectives. In addition to its assessment of achievement against each Corporate Objective, the Board may consider Trevena's performance as a whole during the fiscal year, including matters not included in the Corporate Objectives. Following the determination of the corporate achievement, the Committee will consider the individual achievement of each executive officer and Vice President in arriving at the individual Awards, if any, to be made.

The Compensation Committee approves the pool of Award dollars available for payment to all participants at or below the level of Vice President, as well as the specific individual Awards to be made to the Company's executive officers (other than the President and CEO). The Board approves the individual Award to be made to the President and CEO, upon the recommendation of the Compensation Committee.

The Board's determination of the Company's level of achievement against the Corporate Objectives is the basis for establishing the funding available for Awards under the ICP. An Award is then determined for each participant based upon management's determination of such participant's performance against his or her pre-approved individual goals. Notwithstanding these determinations, the Committee and the Board each retain the discretion to make individual Awards that are above or below the level of corporate achievement. The Committee believes this flexibility is an important tool to aid in the retention of key talent, reward significant achievement by individual employees, motivate employees and recognize management decision-making focused on generating long-term value for stockholders over short-term achievement of the Corporate Objectives. The Committee did not exercise this discretion in 2018.

In January 2018, the Board established the corporate goals and weightings for 2018 that would be used to determine the range of potential aggregate funding for awards under the ICP. In early 2019, the Board, upon the recommendation of the Compensation Committee, assessed the Company's actual performance against these previously established goals and approved the Company's corporate achievement for 2018 at a level of 70% of target.

In determining the amount of each NEO's ICP Award, the Compensation Committee and the Board also considered an NEO's performance against individual goals and the CEO's input with respect to the performance of the Company and the other executive officers. Based on these considerations, the Board approved an ICP Award of \$146,719 for Ms. Bourdow and the Compensation Committee approved, and the Board ratified, ICP Awards of \$103,950 for Dr. Demitrack and \$99,712 for Mr. Limongelli.

Table of Contents

**Long-Term Incentives**

**Key Features**

- Long-term incentives (LTI) are administered under the Trevena, Inc. 2013 Equity Plan.
- Total annual LTI awards are positioned at the 50<sup>th</sup> percentile of the primary market reference for each NEO but with the opportunity to stretch to the 75<sup>th</sup> percentile, as deemed appropriate.
- LTI awards are delivered through stock options.
- The actual realized value of stock options depends upon stock price appreciation (if any) until the option is exercised. The term of the option is 10 years.
- Stock options generally vest (or first become exercisable) in equal quarterly installments over four years. The annual grant is made in the first quarter.

Our 2013 Equity Plan authorizes us to make grants to eligible recipients of non-qualified stock options, incentive stock options, restricted stock awards, restricted stock units and stock appreciation rights. While our equity grants during 2016 and 2017 to our executive officers consisted only of stock options, in December 2018, the Company granted restricted stock unit (RSU) awards of 250,000 shares to Ms. Bourdow with a grant date fair value of \$162,500 and 125,000 shares to Dr. Demitrack with a grant date fair value of \$81,250. In each case, 25% of the total number of shares subject to the RSU award shall vest on June 1, 2019, 25% of the total number of shares subject to the RSU award shall vest on December 1, 2019, and 50% of the total number of shares subject to the RSU award shall vest on December 6, 2020.

We typically grant equity incentive awards at the start of employment to each executive and our other employees. Beginning in 2014, we began our current practice of granting additional equity on an annual basis. We also have discretion to provide additional targeted grants in certain circumstances and/or in association with promotions.

We award our equity grants on the date the Board or the Compensation Committee approves the grant. We set the option exercise price and grant date fair value based on our closing sale price on the date of grant. For grants in connection with initial employment, vesting begins on the initial date of employment. Options have a term of ten years from the grant date. Option grants to our executives typically vest annually over four years.

Edgar Filing: TREVENA INC - Form DEF 14A

The table below provides information regarding stock option awards made in 2018 to the NEOs.

Name	Grant Date	Approval Date	Number of Securities Underlying Options (#)	Exercise Price of Option Awards (\$/Sh)	Closing Market Price on Date of Grant (\$/Sh)	Grant Date Fair Market Value of Option Awards (\$)
Carrie L. Bourdow	02/28/2018	02/28/2018	124,000	1.79	1.79	151,555
	02/28/2018	02/28/2018	112,500	1.79	1.79	133,615
	02/28/2018	02/28/2018	112,500	1.79	1.79	132,603
	09/27/2018	09/27/2018	335,000	2.25	2.25	516,850
	12/6/2018	12/6/2018	250,000	0.65	0.65	106,687
Mark A. Demitrack, M.D.	05/21/2018	05/21/2018	200,000	1.78	1.78	243,927
John M. Limongelli	02/28/2018	02/28/2018	44,000	1.79	1.79	53,777
	02/28/2018	02/28/2018	65,000	1.79	1.79	77,200
	02/28/2018	02/28/2018	65,000	1.79	1.79	76,615

Number of Securities Underlying Options

These amounts represent stock option awards granted under the 2013 Equity Plan (with the exception of Dr. Demitrack's 05/21/2018 grant which was issued in accordance with Company's 2017 Inducement Plan) and approved by the Board of Directors as part of each NEO's annual long-term equity incentive award. For Ms. Bourdow, Mr. Limongelli, and Dr. Gowen, the grants on February 28, 2018 of 124,000, 44,000, and 150,000 stock options, respectively, vest on a quarterly basis over four years, the first grants of 112,500, 65,000, and 252,500, respectively, vest on an annual basis over two years, and the second grants of 112,500, 65,000, and 252,500, respectively, vest upon the satisfaction of a specified performance condition. For Ms. Bourdow, the grant on September 27, 2018 of 335,000 stock options vests on a quarterly basis over four years. For Ms. Bourdow and Dr. Demitrack, the grants on

Table of Contents

December 6, 2018 of 250,000 and 125,000, respectively, vest 25% of the total number of shares subject to the option on June 1, 2019, 25% of the total number of shares subject to the option on December 1, 2019, and 50% of the total number of shares subject to the option on December 6, 2020. For Dr. Demitrack, the grant on May 21, 2018 of 200,000 stock options vests on a quarterly basis over four years.

Exercise Price of Option Awards

Pursuant to the 2013 Equity Plan and 2017 Inducement Plan, the stock option exercise price is the closing sale price of Trevena common stock on the date of the award.

Grant Date Fair Market Value of Options Awards

These amounts represent the grant date fair value of equity awards computed in accordance with ASC Topic 718, applying the same model and assumptions Trevena uses for financial statement reporting purposes. The award values represented in the table are theoretical, and may not correspond to the actual value that will be recognized by the NEO. Trevena stock option awards are determined using a Black-Scholes pricing methodology that assumes that all stock options are held to full-term (ten years).

Table of Contents**OUTSTANDING EQUITY AWARDS AT YEAR-END 2018**

This table provides information about unexercised stock options held as of December 31, 2018 by each of the NEOs.

Name	Grant Date	Option Awards				Stock Awards		
		Number of Securities Underlying Unexercised Options		Equity Incentive Plan: Number of Securities Underlying Unexercised Options (#)(1)	Option Exercise Price (\$)	Option Expiration Date	Number of Units of Stock That Have Not Vested (#)	Market Value of Units of Stock That Have Not Vested (\$)
<b>Carrie L. Bourdow</b>	5/4/2015	93,750	31,250		6.94	5/4/2025		
	3/3/2016	47,500	47,500		8.82	3/3/2026		
	1/6/2017	13,750	41,250		6.61	1/6/2027		
	3/2/2017	22,750	68,250		4.13	3/2/2027		
	8/28/2017	20,625	45,375		2.37	8/28/2027		
	2/28/2018	23,250	100,750		1.79	2/28/2028		
	2/28/2018		112,500		1.79	2/28/2028		
	2/28/2018			112,500	1.79	2/28/2028		
	9/27/2018	20,938	314,062		2.25	9/27/2028		
	12/6/2018		250,000		0.65	12/6/2028		
	12/6/2018						250,000	107,500
<b>Total</b>		<b>242,563</b>	<b>1,010,937</b>	<b>112,500</b>			<b>250,000</b>	<b>107,500</b>
<b>Mark A. Demitrack, M.D.</b>	5/21/2018	25,000	175,000		1.78	5/21/2028		
	12/6/2018		125,000		0.65	12/6/2028		
	12/6/2018						125,000	53,750
<b>Total</b>		<b>25,000</b>	<b>300,000</b>				<b>125,000</b>	<b>53,750</b>
<b>John M. Limongelli</b>	5/14/2014	100,000			4.78	5/14/2024		
	3/17/2015	52,500	17,500		6.79	3/17/2025		
	3/3/2016	59,375	59,375		8.82	3/3/2026		
	1/6/2017	13,750	41,250		6.61	1/6/2027		
	3/2/2017	22,750	68,250		4.13	3/2/2027		
	8/28/2017	20,625	45,375		2.37	8/28/2027		
	2/28/2018	8,250	35,750		1.79	2/28/2028		
	2/28/2018		65,000		1.79	2/28/2028		
	2/28/2018			65,000	1.79	2/28/2028		
<b>Total</b>		<b>277,250</b>	<b>332,500</b>	<b>65,000</b>				
<b>Maxine Gowen, Ph.D.</b>	6/17/2013	382,089			2.23	6/17/2023		
	9/26/2013	104,838			7.44	9/26/2023		
	2/20/2014	175,000			7.40	2/20/2024		
	3/17/2015	225,000	75,000		6.79	3/17/2025		
	3/3/2016	87,500	262,500		8.82	3/3/2026		
	1/6/2017	43,750	131,250		6.61	1/6/2027		
	3/2/2017	75,750	227,250		4.13	3/2/2027		
	8/28/2017	70,313	154,687		2.37	8/28/2027		
	2/28/2018	28,125	121,875		1.79	2/28/2028		
	2/28/2018		252,500		1.79	2/28/2018		
	2/28/2018			252,500	1.79	2/28/2018		
<b>Total</b>		<b>1,279,865</b>	<b>1,137,562</b>	<b>252,500</b>				





Table of Contents

(1) The following table details the future vesting dates of stock options (including performance-based stock options) that have not vested as of December 31, 2018 for the NEOs.

	Number of Stock Options That Have Not Vested	Next Vesting Date from 12/31/2018	Next Vesting Amount	Remaining Vesting Terms
<b>Carrie L. Bourdow</b>	31,250	5/4/2019	31,250	1/4th of total grant every year
	47,250	3/3/2019	23,750	1/4th of total grant every year
	41,250	1/6/2019	13,750	1/4th of total grant every year
	68,250	3/2/2019	22,750	1/4th of total grant every year
	45,375	2/28/2019	4,125	1/16th of total grant every quarter
	100,750	2/28/2019	7,750	1/16th of total grant every quarter
	112,500	2/28/2019	56,250	1/2 of the total grant every year
	112,500			Will vest in full upon satisfaction of a performance condition
	314,062	3/27/2019	20,937	1/16th of total grant every quarter
	250,000	6/1/2019	62,500	1/4th and 1/2 of total grant on 12/1/19 and 12/6/20, respectively
<b>Mark A. Demitrack, M.D.</b>	175,000	2/21/2019	12,500	1/16th of total grant every quarter
	125,000	6/1/2019	31,250	1/4th and 1/2 of total grant on 12/1/19 and 12/6/20, respectively
<b>John M. Limongelli</b>	17,500	3/17/2019	17,500	1/4th of total grant every year
	59,375	3/3/2019	29,688	1/4th of total grant every year
	41,250	1/6/2019	13,750	1/4th of total grant every year
	68,250	3/2/2019	22,750	1/4th of total grant every year
	45,375	2/28/2019	4,125	1/16th of total grant every quarter
	35,750	2/28/2019	2,750	1/16th of total grant every quarter
	65,000	2/28/2019	32,500	1/2 of the total grant every year

Edgar Filing: TREVENA INC - Form DEF 14A

	65,000			Will vest in full upon satisfaction of a performance condition
<b>Maxine Gowen, Ph.D.</b>	75,000	3/17/2019	75,000	1/4th of total grant every year
	262,500	3/3/2019	87,500	1/4th of total grant every year
	131,250	1/6/2019	43,750	1/4th of total grant every year
	227,250	3/2/2019	75,750	1/4th of total grant every year
	154,687	2/28/2019	14,062	1/16th of total grant every quarter
	121,875	2/28/2019	9,375	1/16th of total grant every quarter
	252,500	2/28/2019	126,500	1/2 of the total grant every year
	252,500			Will vest in full upon satisfaction of a performance condition

**EXECUTIVE OFFICER AGREEMENTS**

**Agreements with our Named Executive Officers**

Below are summaries of our employment agreements with our named executive officers who are employed by the Company as of December 31, 2018. All change of control benefits are double-trigger, which means that they are payable only upon a change of control followed by termination of employment. Additionally, in connection with any actual termination of employment or change of control transaction, we may decide to enter into an agreement or to establish an arrangement providing additional benefits or amounts, or altering the terms of the benefits described below, as the Compensation Committee determines appropriate.

**Agreement with Ms. Bourdow**

We entered into an employment agreement with Ms. Bourdow in May 2015. This agreement was subsequently amended in January 2017 and amended and restated on February 1, 2018. In connection with her appointment as President and Chief Executive Officer of the Company in October 2018, the Company and Ms. Bourdow entered into a new employment agreement. Pursuant to this agreement, Ms. Bourdow is entitled to an initial

Table of Contents

annual base salary of \$500,000 (subject to review and adjustment) and is eligible to receive an annual target bonus of up to 60% of her current base salary, as determined by our Board. Ms. Bourdow is additionally entitled to severance benefits pursuant to her agreement, the terms of which are described below under Potential Payments Upon Termination of Employment or in Connection with Change of Control.

**Agreement with Dr. Demitrack**

We entered into an employment agreement with Dr. Demitrack that became effective in May 2018. Pursuant to the agreement, Dr. Demitrack is entitled to an initial annual base salary of \$365,000 (subject to review and adjustment) and is eligible to receive an annual target bonus of up to 40% of his current base salary, as determined by our Board. Dr. Demitrack is additionally entitled to severance benefits pursuant to his agreement, the terms of which are described below under Potential Payments Upon Termination of Employment or in Connection with Change of Control.

**Agreement with Mr. Limongelli**

We entered into an employment agreement with Mr. Limongelli in May 2014. This agreement was subsequently amended in May 2015 and January 2017. Pursuant to the agreement, Mr. Limongelli is entitled to an initial annual base salary of \$300,000 (subject to review and adjustment) and is eligible to receive an annual target bonus of up to 35% of his current base salary, as determined by our Board. Mr. Limongelli is additionally entitled to severance benefits pursuant to his agreement, the terms of which are described below under Potential Payments Upon Termination of Employment or in Connection with Change of Control. Mr. Limongelli resigned from the Company as of March 1, 2019.

**Potential Payments Upon Termination of Employment or in Connection With Change in Control**

*Trevena does not provide executive officers with any single-trigger payments (triggered solely by a change of control), golden parachute excise tax gross-ups or excise tax reimbursements upon a change of control.*

We believe that reasonable severance benefits for our NEOs are important because it may be difficult for them to find comparable employment within a short period of time. We also believe that it is important to protect our NEOs in the event of a change of control transaction involving our company, as a result of which such officers might have their employment terminated. In addition, we believe that the interests of management should be aligned with those of our stockholders as much as possible, and we believe that providing protection upon a change of control is an appropriate counter to any disincentive such officers might otherwise perceive in regard to transactions that may be in the best interest of our stockholders.

As a result of these considerations, we have entered into employment agreements with Ms. Bourdow, Dr. Demitrack, and Mr. Limongelli that provide for specified benefits to be paid if the executives are terminated under specified conditions or in connection with a change in control of our company. Summaries of these benefits are set forth above.

## Edgar Filing: TREVENA INC - Form DEF 14A

Under the employment agreements between us and Ms. Bourdow, Dr. Demitrack, and Mr. Limongelli, if the executive is terminated by us other than for cause or resigns for good reason, in each case as defined in the agreement, he or she will receive:

- continuing payments of her salary as severance pay in the amount of fifteen (15) months of her then-current base salary for Ms. Bourdow, and twelve (12) months of the then-current base salary for each of Dr. Demitrack and Mr. Limongelli, in each case paid in equal installments following termination on our regularly scheduled payroll dates;
- an incentive compensation award for the fiscal year immediately preceding the date of termination, to the extent not already paid, in an amount determined by the Board or Compensation Committee in their sole discretion;
- his or her target annual incentive compensation for the year of termination, pro-rated for the period between the beginning of the calendar year and the date of termination, paid within sixty days following termination;
- for Ms. Bourdow only, an additional amount equal to fifteen (15) months of her target incentive award in effect at the time of termination, payable in equal installments on our regularly scheduled payroll dates over the period that the severance pay is paid,

Table of Contents

- health insurance premiums under our group health insurance plans as provided under the Consolidated Omnibus Budget Reconciliation Act, or COBRA, until the earlier of (i) fifteen (15) months after termination of employment for Ms. Bourdow, and twelve (12) months after termination of employment for Dr. Demitrack and Mr. Limongelli, (ii) such time as the executive is eligible for substantially equivalent health insurance coverage with a subsequent employer and (iii) such time as the executive is no longer eligible for COBRA coverage; and
- accelerated vesting as to that number of unvested shares subject to any outstanding equity awards held by the executive at the time of termination that would have otherwise vested if the executive had remained employed by us for twelve (12) months following the date of termination for Ms. Bourdow, and nine (9) months following the date of termination for Dr. Demitrack and Mr. Limongelli.

In addition, under the employment agreements if the executive is terminated by us other than for cause or resigns for good reason within thirty (30) days prior to a change of control, within the period between our execution of a letter of intent for a change of control and the date that change of control is later consummated, or within twelve months following a change of control, in each case as defined in the agreement, he or she will receive the following payments in lieu of the severance payments listed above:

- continuing payments of his or her salary as severance pay in the amount of twenty-one (21) months of her then-current base salary for Ms. Bourdow, and fifteen (15) months of the then-current base salary for Dr. Demitrack and Mr. Limongelli, in each case paid in equal installments following termination on our regularly scheduled payroll dates;
- an incentive compensation award for the fiscal year immediately preceding the date of termination, to the extent not already paid, in an amount determined by the Board or Compensation Committee in their sole discretion;
- his or her target annual incentive compensation for the year of termination, pro-rated for the period between the beginning of the calendar year and the date of termination, paid within sixty days following termination;
- for Ms. Bourdow, an additional amount equal to twenty-one (21) months of her target bonus in effect at the time of termination, and for Dr. Demitrack and Mr. Limongelli, an additional amount equal to fifteen (15) months of their respective target bonus in effect at the time of termination, in each case payable in equal installments on our regularly scheduled payroll dates over the period that the severance pay is paid;
- health insurance premiums under our group health insurance plans as provided under the COBRA until the earlier of (i) twenty-one (21) months after termination of employment for Ms. Bourdow, and fifteen (15) months after termination of employment for Dr. Demitrack and Mr. Limongelli, (ii) such time as the executive officer is eligible for substantially equivalent health insurance coverage with a subsequent employer and (iii) such time as the executive is no longer eligible for COBRA coverage; and
- accelerated vesting of all unvested shares subject to any outstanding equity awards held by the executive at the time of termination.

Receipt of the benefits described above upon the officer's termination of employment is contingent upon his or her signing of a release of claims against us.

Under the employment agreements, a mere change of control itself (i.e., a single trigger ) does not trigger benefits. The intent of the plan is to encourage executives to continue to act in stockholders' best interests in evaluating potential transactions and ensure management talent will be available to assist with the transaction and business integration.

Table of Contents

## OWNERSHIP OF TREVENA COMMON STOCK

**SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS, DIRECTORS AND EXECUTIVE OFFICERS**

The following table provides information as of March 15, 2019 about the amount of Trevena common stock beneficially owned by (1) all those known by us to be beneficial owners of more than five percent of our common stock; (2) each director and nominee for director; (3) each executive officer named in the 2018 Summary Compensation Table who remains an employee of the Company as of March 15, 2019; and (4) all of the directors, nominees and executive officers of the Company as of March 15, 2019, as a group. This table is based upon information supplied by officers and directors as of March 15, 2019 and Schedules 13D and 13G filed with the SEC by beneficial owners of more than five percent of our common stock (reflecting holdings as of the respective dates set forth therein).

Beneficial ownership includes those shares a director, nominee or executive officer has or shares the power to vote or transfer (even if another person is the record owner), and stock options that are exercisable as of March 15, 2019 or that become exercisable within 60 days of March 15, 2019. Shares of common stock subject to such options are deemed outstanding for calculating the Percent of Class of the person holding these options but are not deemed outstanding for any other person. The Percent of Class shown below is based on 92,353,638 shares outstanding on March 15, 2019.

Unless otherwise noted, the address for each director and executive officer is c/o Trevena, Inc., 955 Chesterbrook Boulevard, Suite 110, Chesterbrook, PA 19087.

	Amount of Beneficial Ownership	Percent of Class
<i>Principal Stockholders:</i>		
Sabby Management, LLC(1)	5,000,000	5.4%
<i>Non-employee Directors and Nominees(2)</i>		
Leon O. Moulder, Jr.	209,836	*
Scott Braunstein, M.D.	10,000	*
Michael R. Dougherty	72,481	*
Maxine Gowen, Ph.D.	2,181,564	2.3%
Julie H. McHugh	56,611	*
Jake R. Nunn	52,011	*
Anne M. Phillips, M.D.	56,611	*
Barbara Yanni	57,861	*
<i>Named Executive Officers(3)</i>		
Carrie L. Bourdow	477,625	*
Mark A. Demitrack, M.D.	37,500	*
All Directors, Nominees and Executive Officers as a group, including those named above (12 Persons)(4)	3,227,787	3.4%

\* Represents beneficial ownership of less than 1%.



- (1) Based on a Schedule 13G filed with the SEC on February 4, 2019, consists of 2,000,000 shares of common stock held of record by Sabby Healthcare Master Fund, Ltd. ( SHMF ) and 3,000,000 shares of common stock held by Sabby Volatility Warrant Master Fund, Ltd. ( SVWMF ). Sabby Management, LLC, ( SM ) serves as investment manager of SHMF and SVWMF and Hal Mintz serves as manager of SM and, as such, each indirectly owns the shares held by SHMF and SVWMF. SM and Hal Mintz share voting and dispositive power with regard to the shares held directly by SHMF and SVWMF. The principal business address of the beneficial owners is, for SHMF and SVWMF, c/o Ogier Fiduciary Services (Cayman) Limited, 89 Nexus Way, Camana Bay, Grand Cayman KY1-9007, Cayman Islands and, for SM and Hal Mintz, 10 Mountainview Road, Suite 205, Upper Saddle River, New Jersey 07458.
- (2) Includes shares of common stock issuable upon the exercise of options exercisable within 60 days after March 15, 2019 in the amount of 59,836 for Mr. Moulder; 65,481 for Mr. Dougherty; 1,711,552 for Dr. Gowen; 56,611 for Ms. McHugh; 47,740 for Mr. Nunn; 56,611 for Dr. Phillips; 10,000 for Dr. Braunstein; and 56,611 for Ms. Yanni.
- (3) Includes shares of common stock issuable upon the exercise of options exercisable within 60 days after March 15, 2018 in the amount of 423,125 for Ms. Bourdow and 37,500 for Dr. Demitrack. Mr. Limongelli resigned from the Company on March 1, 2019 and is not included in this table.
- (4) Includes shares of common stock issuable upon the exercise of options exercisable within 60 days after March 15, 2018 in the amount of 2,488,629 for all of the directors, nominees for director and executive officers, as a group.

Table of Contents

**SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE**

Trevena's directors and executive officers are required to file reports of their holdings and transactions in Trevena securities with the SEC. Based on the reports and representations from our directors and executive officers, the Company believes that all reports due in 2018 were timely filed.

Table of Contents

2020 ANNUAL MEETING AND RELATED MATTERS

**When do you expect to hold the 2020 annual meeting of stockholders?**

We currently expect to hold the 2020 Annual Meeting in May 2020, at a time and location to be announced later.

**How does a stockholder submit a proposal or nomination of a director candidate for the 2020 annual meeting?**

The following summarizes the requirements for stockholder proposals to be considered for inclusion in next year's proxy materials.

- If you intend to submit a proposal to be included in next year's proxy materials pursuant to SEC Rule 14a-8, the Corporate Secretary must receive your proposal on or before December 4, 2019. Submitting a stockholder proposal does not guarantee that Trevena will include the proposal in the proxy statement if the proposal does not satisfy the SEC's rules.
- If you want to present your proposal at the 2020 annual meeting but are not proposing it pursuant to SEC Rule 14a-8, the Corporate Secretary must receive your proposal by the close of business between January 17, 2020 and February 16, 2020 and it must satisfy the requirements set forth in Article III, Section 5 of our Amended and Restated Bylaws.

If you would like to nominate a candidate for director at the 2020 annual meeting, you must notify the Corporate Secretary by the close of business between January 17, 2020 and February 16, 2020. The notice must include certain information specified in our Amended and Restated Bylaws, including (i) your name and address, (ii) the class and number of shares of our stock which you beneficially own, (iii) the name, age, business address and residence address of the person, (iv) the principal occupation or employment of the person, (v) the class and number of shares of our stock which are owned of record and beneficially owned by the person, (vi) the date or dates on which such shares were acquired and the investment intent of such acquisition and (vii) any other information concerning the person as would be required to be disclosed in a proxy statement soliciting proxies for the election of that person as a director in an election contest (even if an election contest is not involved), or that is otherwise required to be disclosed pursuant to Section 14 of the Securities Exchange Act of 1934 and the rules and regulations promulgated thereunder (including the person's written consent to being named as a nominee and to serving as a director if elected). We may require any proposed nominee to furnish such other information as we may reasonably require to determine the eligibility of such proposed nominee to serve as an independent director of the Company or that could be material to a reasonable stockholder's understanding of the independence, or lack thereof, of such proposed nominee.

Correspondence to the Corporate Secretary may be addressed to: Corporate Secretary, Trevena, Inc., 955 Chesterbrook Boulevard, Suite 110, Chesterbrook, PA 19087. For more information, and for more detailed requirements, please refer to our Amended and Restated Bylaws, filed as Exhibit 3.2 to our Current Report on Form 8-K, filed with the SEC on February 5, 2014.

**How can I communicate with the Board of Directors?**

Stockholders and interested parties may contact the Board of Directors, the Chairman, the independent directors, or specific individual directors by sending written correspondence to the Board, Attention: Corporate Secretary, Trevena, Inc., 955 Chesterbrook Boulevard, Suite 110, Chesterbrook, PA 19087.

The Corporate Secretary will compile all communications other than routine commercial solicitations and opinion surveys sent to Board members and periodically submit them to the Board. Communications addressed to individual directors at the director address will be promptly submitted to such individual directors. The Corporate Secretary also will promptly advise the appropriate member of management of any concerns relating to Trevena's products or services, and the Corporate Secretary will notify the Board of the resolution of those concerns.

Table of Contents

**How do I obtain copies of Trevena's corporate governance and other company documents?**

The Corporate Governance Guidelines, committee charters and Trevena's Code of Ethics are posted at [investors.trevena.com/corporate-governance](http://investors.trevena.com/corporate-governance). In addition, these documents are available in print to any stockholder who submits a written request to the Corporate Secretary at the address listed above.

The Company's filings with the SEC, including its annual report on Form 10-K, are available through [investors.trevena.com/financial-information/sec-filings](http://investors.trevena.com/financial-information/sec-filings).

If you are a stockholder and did not receive an individual copy of this year's proxy statement or annual report, we will promptly send a copy to you if you address a written request to Investor Relations, Trevena, Inc., 955 Chesterbrook Boulevard, Suite 110, Chesterbrook, PA 19087.

**What is householding and how does it affect me?**

If you and other residents at your mailing address own shares of Trevena stock in street name, your broker or bank should have notified you that your household will receive only one proxy statement and annual report or notice of Internet availability of proxy materials, but each stockholder who resides at your address will receive a separate proxy card or voting instruction form. This practice is known as householding. Unless you responded that you did not want to participate in householding, you were deemed to have consented to the process. Householding benefits both you and Trevena because it reduces the volume of duplicate information received at your household and helps Trevena reduce expenses and conserve natural resources.

If you would like to receive your own set of Trevena's proxy statement and annual report or, if applicable, your own notice of Internet availability of proxy materials now or in the future, or if you share an address with another Trevena stockholder and together both of you would like to receive only a single set of Trevena's proxy materials, please contact Broadridge, Household Department, 51 Mercedes Way, Edgewood, NY 11717 or (800) 542-1061. The request must be made by each person in the household. Be sure to indicate your name, the name of your brokerage firm or bank, and your account number. The revocation of your consent to householding will be effective 30 days following its receipt.













